albendazole has been researched along with Central Nervous System Cysticercosis in 279 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Children with persistent neurocysticercosis were randomized into 3 groups-albendazole (n = 19), albendazole and praziquantel (n = 21), and placebo (n = 20)-for 30 days and followed up at 3 and 6 months for resolution and recurrence of seizures." | 9.51 | Efficacy of Combination Therapy of Albendazole and Praziquantel vs Albendazole Monotherapy in Children With Persistent Neurocysticercosis: A Randomized Controlled Trial. ( Khandelwal, N; Saini, AG; Singh, K; Singhi, P, 2022) |
| "There is a paucity of literature to support 14-days albendazole therapy for neurocysticercosis (NCC)." | 9.51 | Fourteen Days vs 28 Days of Albendazole Therapy for Neurocysticercosis in Children: An Open Label Randomized Controlled Trial. ( Dabla, S; Kaushik, JS; Lekhwani, S; Singla, A; Vaswani, ND, 2022) |
| "Albendazole treatment is associated with a possible reduction in focal seizures in the short term (3-6 months), perhaps by hastening the resolution of the cysts." | 9.30 | Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis. ( Carpio, A; Chang, M; Hauser, WA; Jaramillo, A; Kelvin, EA; Romo, ML; Zhang, H, 2019) |
| "In this trial, 178 patients with active or transitional neurocysticercosis cysts and new-onset symptoms were randomized to 8 days of treatment with albendazole (n=88) or placebo (n=90), both with prednisone, and followed for 24 months." | 9.20 | The effect of albendazole treatment on seizure outcomes in patients with symptomatic neurocysticercosis. ( Andrews, H; Bagiella, E; Carpio, A; Hauser, WA; Kelvin, EA; Leslie, D; Romo, ML; Wyka, K, 2015) |
| "In this double-blind, placebo-controlled, phase 3 trial, patients with viable intraparenchymal neurocysticercosis were randomly assigned to receive 10 days of combined albendazole (15 mg/kg per day) plus praziquantel (50 mg/kg per day), standard albendazole (15 mg/kg per day), or increased dose albendazole (22·5 mg/kg per day)." | 9.19 | Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. ( Bustos, JA; Escalante, D; Garcia, HH; Gavidia, M; Gonzales, I; Lescano, AG; Najar, E; Pretell, EJ; Rodriguez, L; Saavedra, H; Umeres, H; Zimic, M, 2014) |
| "Albendazole therapy has been found effective in solitary cysticercus granuloma." | 9.16 | Three-day versus 15-day course of albendazole therapy in solitary cysticercus granuloma: an open label randomized trial. ( Garg, RK; Khurana, N; Malhotra, HS; Shukla, R; Singh, MK; Verma, R, 2012) |
| "To evaluate the efficacy and safety of a combination of albendazole and praziquantel in children with seizures and single small enhancing computerized tomographic lesions." | 9.14 | Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. ( Kaur, S; Khandelwal, N; Singhi, P; Singhi, S, 2009) |
| "To evaluate the response to albendazole treatment in patients who had SSECTL and new onset seizures treated with antiepileptic drugs (AED) in a prospective clinical trial." | 9.13 | Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy. ( Chattopadhyay, A; Khandelwal, N; Sawhney, IM; Thussu, A, 2008) |
| "The aim of this trial was to evaluate the effects of albendazole (ALB) on cyst disappearance, reduction of the number of cysts and seizure recurrence." | 9.13 | Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. ( Andrews, H; Bagiella, E; Carpio, A; Hauser, WA; Kelvin, EA; Leon, P; Leslie, D, 2008) |
| "The appropriate duration of albendazole therapy in neurocysticercosis remains to be determined." | 9.10 | One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial. ( Dayal, D; Khandelwal, N; Singhi, P, 2003) |
| "Albendazole plus dexamethasone increased complete or partial resolution of lesions and reduced the risk of subsequent recurrence of seizures among children with neurocysticercosis who had with seizures and 1 or 2 ring-enhancing lesions on computed tomography." | 9.10 | Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. ( Dua, T; Kalra, V; Kumar, V, 2003) |
| "The enantioselectivity of the kinetic disposition of albendazole sulfoxide (ASOX) was investigated in 18 patients with neurocysticercosis treated with a multiple dose regimen of albendazole for 8 days (5 mg/kg every 8 h)." | 9.09 | Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. ( Bonato, PS; Lanchote, VL; Marques, MP; Santos, SR; Takayanagui, OM, 1999) |
| "Use of Albendazole therapy for the treatment of patients having persisting intracranial solitary cysticercus granuloma is controversial." | 9.09 | Albendazole therapy for solitary persistent cysticercus granuloma. ( Arora, A; Lal, V; Prabhakar, S; Sawhney, IM; Thussu, A, 2001) |
| "To evaluate the efficacy of albendazole in cases of focal seizures with SSECTLs." | 9.08 | Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial. ( Baranwal, AK; Khandelwal, N; Singhi, PD; Singhi, SC, 1998) |
| "A recent trial suggested that albendazole reduces seizures in adults with neurocysticercosis." | 8.84 | Does albendazole affect seizure remission and computed tomography response in children with neurocysticercosis? A Systematic review and meta-analysis. ( Mazumdar, M; Pandharipande, P; Poduri, A, 2007) |
| "A critical review of the available data from comparative trials suggests that albendazole is more effective than praziquantel regarding clinically important outcomes in patients with neurocysticercosis." | 8.84 | Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. ( Adamidi, ES; Falagas, ME; Matthaiou, DK; Panos, G, 2008) |
| "The objective was to compare the long-term clinical, radiological, and cognitive outcomes in children with single-lesion neurocysticercosis who received 7 or 28 days of albendazole therapy." | 8.12 | Comparison of Long-Term Outcomes Between 7 Days and 28 Days Albendazole Monotherapy in the Treatment of Single-Lesion Neurocysticercosis in Children. ( Johnson, N; Khandelwal, N; Malhi, P; Saini, AG; Singhi, P, 2022) |
| "The efficacy of albendazole therapy in patients with parenchymal neurocysticercosis (NCC) is suboptimal." | 7.91 | Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis. ( Arroyo, G; Bonato, PS; Bustos, JA; Garcia, HH; Gilman, RH; Gonzales, I; Gonzalez, AE; Horton, J; Lanchote, VL; Lescano, AG; Pretell, EJ; Rodriguez, S; Saavedra, H; Takayanagui, OM, 2019) |
| "To determine a population pharmacokinetic model of the antihelmintic drug, albendazole, and identify the factors influencing the pharmacokinetic parameters in patients with neurocysticercosis." | 7.75 | Population pharmacokinetics of albendazole in patients with neurocysticercosis. ( Brundage, RC; Castro, N; Góngora, F; González-Esquivel, D; Jara, A; Jung, H; Lanao, JM; Márquez-Caraveo, C; Suárez, AM; Urizar, J, 2009) |
| " We report a case in which treatment with high-dose praziquantel resulted in prolonged perilesional edema requiring use of corticosteroids and corticosteroid-sparing agents for >1 year, suggesting a role for methotrexate in the management of this condition." | 7.72 | Prolonged perilesional edema after treatment of parenchymal neurocysticercosis: methotrexate as a corticosteroid-sparing agent. ( Keiser, PB; Nash, TE, 2003) |
| "The present study investigates the urinary excretion of the enantiomers of (+)- and (-)-albendazole sulfoxide (ASOX) and albendazole sulfone (ASON) in 12 patients with neurocysticercosis treated with albendazole for 8 days (7." | 7.72 | Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis. ( Lanchote, VL; Mateus, FH; Takayanagui, OM, 2004) |
| "Albendazole (ABZ) is effective in the treatment of neurocysticercosis." | 7.71 | Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis. ( Bonato, PS; Dreossi, SA; Lanchote, VL; Takayanagui, OM, 2002) |
| "The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug." | 7.71 | Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450. ( Lanchote, VL; Marques, MP; Takayanagui, OM, 2002) |
| "Albendazole's impact was stronger for patients who were male, did not have calcified cysts at baseline and who had multiple cysts in different locations." | 6.90 | A longitudinal analysis of albendazole treatment effect on neurocysticercosis cyst evolution using multistate models. ( Carpio, A; Hauser, WA; Jaramillo, A; Kelvin, EA; Montgomery, MA; Ramos, M; Zhang, H, 2019) |
| "Albendazole (ABZ) has been used together with praziquantel (PZQ) before for geohelminths, echinococcosis and cysticercosis, but their combined use is not yet formally recommended and only scarce, discrepant data exist on their pharmacokinetics when given together." | 6.76 | Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. ( Bonato, PS; Bustos, JA; Garcia, HH; Gilman, RH; Gonzales, I; Gonzalez, AE; Horton, J; Lanchote, VL; Lescano, AG; Pretell, EJ; Saavedra, H; Takayanagui, OM, 2011) |
| "Twenty-three patients had seizure recurrence while on antiepilepsy drugs: 36." | 6.71 | Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis. ( Jain, V; Khandelwal, N; Singhi, P, 2004) |
| " The pharmacokinetic parameters were analyzed by analysis of variance followed by the Tukey-Kramer test." | 6.70 | Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ( Dreossi, SA; Garcia, FS; Lanchote, VL; Takayanagui, OM, 2002) |
| "Seizures were present in 94." | 6.69 | Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. ( Khandelwal, N; Ray, M; Singhi, P; Singhi, S, 2000) |
| "Albendazole was given as a single oral dose of 15 mg per kg body weight (Zentel suspension; Smith Kline & Beecham, Philadelphia, PA)." | 6.68 | Clinical pharmacokinetics of albendazole in children with neurocysticercosis. ( González-Astiazarán, A; González-Esquivel, DF; Jung, H; Martínez, JM; Sánchez, M; Suástegui, R, 1997) |
| "55%; P = 0." | 6.43 | Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. ( Coffey, CS; Del Brutto, OH; García, HH; Roos, KL, 2006) |
| "Albendazole treatment leads to a remarkable reduction in neurocysticercosis lesions throughout the body." | 5.91 | Value of whole-body MRI for the assessment of response to albendazole in disseminated neurocysticercosis: a prospective follow-up study. ( Garg, RK; Jain, A; Kumar, N; Malhotra, HS; Malhotra, KP; Pandey, S; Parihar, A; Rizvi, I; Sharma, PK; Uniyal, R; Verma, R; Wangda, K, 2023) |
| "Oxfendazole (OXF) is an albendazole derivative with efficacy against tissue cestodes of veterinary importance." | 5.72 | Oxfendazole induces protein catabolism and gluconeogenesis in experimental neurocysticercosis. ( Correia, LTB; Costa, TL; de Lima, NF; De Sousa Guerra, CH; Gomes, TC; Vinaud, MC, 2022) |
| " Conclusion: Praziquantel is effective and safe in the treatment of patients with neurocysticercosis." | 5.72 | Efficacy and safety of praziquantel in the treatment of neurocysticercosis in Vietnam. ( Loi, CB; Phuc, TQ; Thang, TD; Thanh, DT; Thieu, NQ; Tho, TH; Tran-Anh, L, 2022) |
| "Cysticercosis is a neglected tropical disease set as health priority by WHO." | 5.56 | [Disseminated cysticercosis affecting the brain, the eye and the skin on a Senegalese patient]. ( Diallo, K; Diallo, M; Dione, MAD; Diop, A; Manga, NM; Wembulua, BS, 2020) |
| "Children with persistent neurocysticercosis were randomized into 3 groups-albendazole (n = 19), albendazole and praziquantel (n = 21), and placebo (n = 20)-for 30 days and followed up at 3 and 6 months for resolution and recurrence of seizures." | 5.51 | Efficacy of Combination Therapy of Albendazole and Praziquantel vs Albendazole Monotherapy in Children With Persistent Neurocysticercosis: A Randomized Controlled Trial. ( Khandelwal, N; Saini, AG; Singh, K; Singhi, P, 2022) |
| "There is a paucity of literature to support 14-days albendazole therapy for neurocysticercosis (NCC)." | 5.51 | Fourteen Days vs 28 Days of Albendazole Therapy for Neurocysticercosis in Children: An Open Label Randomized Controlled Trial. ( Dabla, S; Kaushik, JS; Lekhwani, S; Singla, A; Vaswani, ND, 2022) |
| "The onset of anthelmintic treatment of neurocysticercosis (NCC) provokes an acute immune response of the host, which in human cases is associated with exacerbation of neurological symptoms." | 5.46 | Radiological evolution of porcine neurocysticercosis after combined antiparasitic treatment with praziquantel and albendazole. ( Arroyo, G; Bustos, JA; Calcina, J; Cangalaya, C; Chacaltana, J; García, HH; Gonzalez, AE; Guerra-Giraldez, C; Mahanty, S; Mamani, J; Nash, TE; Suarez, D; Vargas-Calla, A, 2017) |
| "Seizures are the primary clinical manifestation which could be acute (secondary to active lesions) or remote symptomatic (due to calcified lesions)." | 5.40 | Seizure and radiological outcomes in children with solitary cysticercous granulomas with and without albendazole therapy: a retrospective case record analysis. ( Chakrabarty, B; Gulati, S; Gupta, AK; Jain, P; Kumar, A; Pandey, RM; Sachan, D, 2014) |
| "Albendazole treatment is associated with a possible reduction in focal seizures in the short term (3-6 months), perhaps by hastening the resolution of the cysts." | 5.30 | Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis. ( Carpio, A; Chang, M; Hauser, WA; Jaramillo, A; Kelvin, EA; Romo, ML; Zhang, H, 2019) |
| "In this trial, 178 patients with active or transitional neurocysticercosis cysts and new-onset symptoms were randomized to 8 days of treatment with albendazole (n=88) or placebo (n=90), both with prednisone, and followed for 24 months." | 5.20 | The effect of albendazole treatment on seizure outcomes in patients with symptomatic neurocysticercosis. ( Andrews, H; Bagiella, E; Carpio, A; Hauser, WA; Kelvin, EA; Leslie, D; Romo, ML; Wyka, K, 2015) |
| "In this double-blind, placebo-controlled, phase 3 trial, patients with viable intraparenchymal neurocysticercosis were randomly assigned to receive 10 days of combined albendazole (15 mg/kg per day) plus praziquantel (50 mg/kg per day), standard albendazole (15 mg/kg per day), or increased dose albendazole (22·5 mg/kg per day)." | 5.19 | Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. ( Bustos, JA; Escalante, D; Garcia, HH; Gavidia, M; Gonzales, I; Lescano, AG; Najar, E; Pretell, EJ; Rodriguez, L; Saavedra, H; Umeres, H; Zimic, M, 2014) |
| "Albendazole therapy has been found effective in solitary cysticercus granuloma." | 5.16 | Three-day versus 15-day course of albendazole therapy in solitary cysticercus granuloma: an open label randomized trial. ( Garg, RK; Khurana, N; Malhotra, HS; Shukla, R; Singh, MK; Verma, R, 2012) |
| "We randomized 123 patients with SCC and new-onset seizures to treatment with albendazole plus antiepileptics (treatment), or antiepileptics only (control), and performed magnetic resonance imaging (MRI) scans at 0, 3, 6, 12, and 24 months." | 5.15 | Perilesional gliosis around solitary cerebral parenchymal cysticerci and long-term seizure outcome: a prospective study using serial magnetization transfer imaging. ( de Souza, A; Kovoor, JM; Nalini, A; Siddalingaiah, HS; Thennarasu, K; Yeshraj, G, 2011) |
| "To evaluate the efficacy and safety of a combination of albendazole and praziquantel in children with seizures and single small enhancing computerized tomographic lesions." | 5.14 | Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. ( Kaur, S; Khandelwal, N; Singhi, P; Singhi, S, 2009) |
| "To evaluate the response to albendazole treatment in patients who had SSECTL and new onset seizures treated with antiepileptic drugs (AED) in a prospective clinical trial." | 5.13 | Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy. ( Chattopadhyay, A; Khandelwal, N; Sawhney, IM; Thussu, A, 2008) |
| "The aim of this trial was to evaluate the effects of albendazole (ALB) on cyst disappearance, reduction of the number of cysts and seizure recurrence." | 5.13 | Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. ( Andrews, H; Bagiella, E; Carpio, A; Hauser, WA; Kelvin, EA; Leon, P; Leslie, D, 2008) |
| "We conducted a double-blind, placebo-controlled trial in which 120 patients who had living cysticerci in the brain and seizures treated with antiepileptic drugs were randomly assigned to receive either 800 mg of albendazole per day and 6 mg of dexamethasone per day for 10 days (60 patients) or two placebos (60 patients)." | 5.11 | A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. ( Del Brutto, OH; Evans, CA; Garcia, HH; Gilman, RH; Gonzalez, AE; Herrera, G; Martinez, SM; Moulton, LH; Pretell, EJ, 2004) |
| "The appropriate duration of albendazole therapy in neurocysticercosis remains to be determined." | 5.10 | One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial. ( Dayal, D; Khandelwal, N; Singhi, P, 2003) |
| "Albendazole plus dexamethasone increased complete or partial resolution of lesions and reduced the risk of subsequent recurrence of seizures among children with neurocysticercosis who had with seizures and 1 or 2 ring-enhancing lesions on computed tomography." | 5.10 | Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. ( Dua, T; Kalra, V; Kumar, V, 2003) |
| "The enantioselectivity of the kinetic disposition of albendazole sulfoxide (ASOX) was investigated in 18 patients with neurocysticercosis treated with a multiple dose regimen of albendazole for 8 days (5 mg/kg every 8 h)." | 5.09 | Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. ( Bonato, PS; Lanchote, VL; Marques, MP; Santos, SR; Takayanagui, OM, 1999) |
| "18 patients with partial epilepsy and neurocysticercosis were treated with albendazol or praziquantel and followed from 3 months to 12 years." | 5.09 | Cysticidal therapy: impact on seizure control in epilepsy associated with neurocysticercosis. ( Cardoso, TM; Cendes, F; Guerreiro, CA; Kobayashi, E; Santos, IC, 2000) |
| "Use of Albendazole therapy for the treatment of patients having persisting intracranial solitary cysticercus granuloma is controversial." | 5.09 | Albendazole therapy for solitary persistent cysticercus granuloma. ( Arora, A; Lal, V; Prabhakar, S; Sawhney, IM; Thussu, A, 2001) |
| "To evaluate the efficacy of albendazole in cases of focal seizures with SSECTLs." | 5.08 | Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial. ( Baranwal, AK; Khandelwal, N; Singhi, PD; Singhi, SC, 1998) |
| "Anthelminthic treatment with albendazole provides improved rates of seizure freedom and hastens resolution of the granuloma." | 4.89 | Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis. ( Otte, WM; Sander, JW; Singh, G; Singla, M, 2013) |
| "A recent trial suggested that albendazole reduces seizures in adults with neurocysticercosis." | 4.84 | Does albendazole affect seizure remission and computed tomography response in children with neurocysticercosis? A Systematic review and meta-analysis. ( Mazumdar, M; Pandharipande, P; Poduri, A, 2007) |
| "A critical review of the available data from comparative trials suggests that albendazole is more effective than praziquantel regarding clinically important outcomes in patients with neurocysticercosis." | 4.84 | Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. ( Adamidi, ES; Falagas, ME; Matthaiou, DK; Panos, G, 2008) |
| " The authors consider the diagnostic, pathologic and clinical elements that allow differential diagnosis with respect to neurocysticercosis, a parasitic infection caused by the larval form of other Cestoda, discussing possible medical therapeutic approaches (albendazole or praziquantel) and neurosurgical intervention." | 4.82 | [A case of cerebral coenurosis]. ( Calbucci, F; Chiodo, F; Roncaroli, F; Sabbatani, S; Zucchelli, M, 2004) |
| "Therapy for neurocysticercosis has advanced during the last 20 years with the advent of albendazole (Zentel) and praziquantel (Cysticide)." | 4.82 | Therapy for neurocysticercosis. ( Takayanagui, OM, 2004) |
| "Four trials met the inclusion criteria, treating intraparenchymatous neurocysticercosis with either albendazole or praziquantel compared to placebo or no treatment." | 4.80 | Treating neurocysticercosis medically: a systematic review of randomized, controlled trials. ( Counsell, C; Garner, P; Gelband, H; Prasad, K; Salinas, R, 1999) |
| "Cyst resolution was unsatisfactory with albendazole monotherapy but was very high when it was followed by a combination of albendazole and praziquantel." | 4.31 | Efficacy and safety of antiparasitic therapy for neurocysticercosis in rural Tanzania: a prospective cohort study. ( Bottieau, E; Carabin, H; Dorny, P; Fleury, A; Gabriël, S; Jackson, E; Magnussen, P; Makasi, C; Mwape, KE; Ngowi, BJ; Prazeres da Costa, C; Prodjinotho, UF; Ruether, C; Schmidt, V; Stelzle, D; Trevisan, C; Van Damme, I; Winkler, AS; Zulu, G, 2023) |
| "The objective was to compare the long-term clinical, radiological, and cognitive outcomes in children with single-lesion neurocysticercosis who received 7 or 28 days of albendazole therapy." | 4.12 | Comparison of Long-Term Outcomes Between 7 Days and 28 Days Albendazole Monotherapy in the Treatment of Single-Lesion Neurocysticercosis in Children. ( Johnson, N; Khandelwal, N; Malhi, P; Saini, AG; Singhi, P, 2022) |
| " Carbamazepine or oxcarbazepine are best suited for seizure prophylaxis for those who present with seizures; phenytoin and levetiracetam are the other alternatives." | 4.02 | Management of Neurocysticercosis in Children: Association of Child Neurology Consensus Guidelines. ( Kadwa, RA; Kamate, M; Kannan, L; Kumar, A; Passi, GR; Sankhyan, N; Sharawat, IK; Singhi, P, 2021) |
| "The current pharmacological treatment of neurocysticercosis is based on two drugs, praziquantel (PZQ) and albendazole; however, suboptimal efficacy has been documented." | 3.96 | Cysticidal activity of praziquantel-mebendazole combination: In vitro and in vivo studies. ( Fernanda, GM; Francisca, PA; Guadalupe, PH; Helgi, JC; Iliana, GH; Javier, LF; Nelly, C; Susana, RI, 2020) |
| "The efficacy of albendazole therapy in patients with parenchymal neurocysticercosis (NCC) is suboptimal." | 3.91 | Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis. ( Arroyo, G; Bonato, PS; Bustos, JA; Garcia, HH; Gilman, RH; Gonzales, I; Gonzalez, AE; Horton, J; Lanchote, VL; Lescano, AG; Pretell, EJ; Rodriguez, S; Saavedra, H; Takayanagui, OM, 2019) |
| "Intranasal Microemulsions (MEs) for nose to brain delivery of a novel combination of Albendazole sulfoxide (ABZ-SO) and Curcumin (CUR) for Neurocysticercosis (NCC), a brain infection are reported." | 3.81 | Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: Role of docosahexaenoic acid. ( Bharkad, GP; Devarajan, PV; Shinde, RL, 2015) |
| " This case of acute hydrocephalus was found to be caused by isolated intraspinal neurocysticercosis and was treated by ventriculoperitoneal shunt placement and surgical removal of the intraspinal lesions (which were histologically confirmed as neurocysticercosis), followed by administration of dexamethasone and albendazole." | 3.80 | Acute hydrocephalus caused by intraspinal neurocysticercosis: case report. ( Ju, CI; Kim, DM; Kim, SW; Wang, HS, 2014) |
| "The available data demonstrate that albendazole therapy, administered with or without corticosteroids, is probably effective in decreasing both long-term seizure frequency and the number of cysts demonstrable radiologically in adults and children with neurocysticercosis, and is well-tolerated." | 3.79 | Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. ( Baird, RA; Gronseth, G; Halperin, JJ; Roos, KL; Wiebe, S; Zunt, JR, 2013) |
| "Albendazole is an anthelmintic drug widely used in the treatment of neurocysticercosis (NCC), an infection of the brain with Taenia solium cysts." | 3.79 | In vitro analysis of albendazole sulfoxide enantiomers shows that (+)-(R)-albendazole sulfoxide is the active enantiomer against Taenia solium. ( Cass, QB; de Campos Lourenço, T; Dorny, P; García, HH; Guerra-Giraldez, C; Mahanty, S; Marzal, M; Nash, TE; Paredes, A; Rivera, A, 2013) |
| " Diagnosis of neurocysticercosis was confirmed by positive serology and response to albendazole therapy." | 3.78 | Neurocysticercosis in a 2-year-old boy infected at home. ( Del Brutto, OH, 2012) |
| " A 32 yr old man on treatment with Albendazole for cerebral neurocysticercosis for 10 days presented with 3 days of painful uniocular blindness." | 3.76 | Monocular blindness during therapy for cerebral neurocysticercosis. ( Asole, D; Chawla, V; Lakkas, Y; Shrivastava, M; Sundar, U; Vaidy, M, 2010) |
| "To determine a population pharmacokinetic model of the antihelmintic drug, albendazole, and identify the factors influencing the pharmacokinetic parameters in patients with neurocysticercosis." | 3.75 | Population pharmacokinetics of albendazole in patients with neurocysticercosis. ( Brundage, RC; Castro, N; Góngora, F; González-Esquivel, D; Jara, A; Jung, H; Lanao, JM; Márquez-Caraveo, C; Suárez, AM; Urizar, J, 2009) |
| " Lastly, widespread neurocysticercosis may be a concern in mass treatment programs that provide praziquantel (for managing schistosomiasis) or albendazole (for managing intestinal worms or lymphatic filariasis) because these drugs may kill cerebral cysticerci, resulting in severe adverse events." | 3.74 | Could neurocysticercosis be the cause of "onchocerciasis-associated" epileptic seizures? ( Eberhard, M; Habumogisha, P; Katabarwa, M; Lakwo, T; Richards, F, 2008) |
| " This presentation was considered characteristic of neurocysticercosis and the patient was prescribed a regimen of 200mg albendazole b." | 3.73 | Bilateral disk edema with unilateral macular serous fluid secondary to neurocysticercosis. ( Barr, R; Besada, E; Natu, A, 2005) |
| "Seven patients with active neurocysticercosis (NCC) received an eight days treatment with albendazole and were followed up using computed tomography (CT-scan) and a monoclonal antibody based ELISA for the detection of circulating antigen (Ag-ELISA)." | 3.72 | Follow-up of neurocysticercosis patients after treatment using an antigen detection ELISA. ( Brandt, J; Dorny, P; Geerts, S; Ongolo-Zogo, P; Zoli, AP, 2003) |
| " We report a case in which treatment with high-dose praziquantel resulted in prolonged perilesional edema requiring use of corticosteroids and corticosteroid-sparing agents for >1 year, suggesting a role for methotrexate in the management of this condition." | 3.72 | Prolonged perilesional edema after treatment of parenchymal neurocysticercosis: methotrexate as a corticosteroid-sparing agent. ( Keiser, PB; Nash, TE, 2003) |
| "The present study investigates the urinary excretion of the enantiomers of (+)- and (-)-albendazole sulfoxide (ASOX) and albendazole sulfone (ASON) in 12 patients with neurocysticercosis treated with albendazole for 8 days (7." | 3.72 | Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis. ( Lanchote, VL; Mateus, FH; Takayanagui, OM, 2004) |
| "To determine the therapeutic efficacy of albendazole combined with surgical intervention on intracranial hypertension in the treatment of severe neurocysticercosis." | 3.72 | [Clinical study on the treatment of severe neurocysticercosis]. ( Ding, YZ; Qiu, MD; Ren, HJ; Wang, WP; Wu, XL; Yuan, Z; Zhang, JS, 2004) |
| "Albendazole (ABZ) is effective in the treatment of neurocysticercosis." | 3.71 | Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis. ( Bonato, PS; Dreossi, SA; Lanchote, VL; Takayanagui, OM, 2002) |
| "The present study investigates the isoform(s) of cytochrome P450 (CYP) involved in the metabolism of albendazole sulfoxide (ASOX) to albendazole sulfone (ASON) in patients with neurocysticercosis using antipyrine as a multifunctional marker drug." | 3.71 | Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450. ( Lanchote, VL; Marques, MP; Takayanagui, OM, 2002) |
| "In this study, 65 patients with active neurocysticercosis (NCC) treated with praziquantel or albendazole were retrospectively reviewed to evaluate radiological and clinical outcome." | 3.70 | Outcomes of medical treatment of neurocysticercosis: a study of 65 cases in Cheju Island, Korea. ( Cho, BK; Hong, KS; Kim, SK; Paek, SH; Wang, KC, 1999) |
| "Neurocysticercosis is a parasitic infection of the central nervous system by tapeworm larvae." | 3.01 | Spinal nerve root sleeve cysticercosis: a case report and review of the literature. ( Ji, K; Li, T; Shang, A; Tao, B, 2023) |
| "Albendazole's impact was stronger for patients who were male, did not have calcified cysts at baseline and who had multiple cysts in different locations." | 2.90 | A longitudinal analysis of albendazole treatment effect on neurocysticercosis cyst evolution using multistate models. ( Carpio, A; Hauser, WA; Jaramillo, A; Kelvin, EA; Montgomery, MA; Ramos, M; Zhang, H, 2019) |
| "Patients with new-onset seizures due to SCC were imaged serially using a pre-determined MRI protocol at enrolment and after 3, 6, 12 and 24months." | 2.84 | T2 relaxometry helps prognosticate seizure outcome in patients with solitary cerebral cysticercosis. ( de Souza, A; Nalini, A; Saini, J; Thennarasu, K, 2017) |
| "Neurocysticercosis is one of the most common parasitic infections in the central nervous system in children." | 2.82 | Neurocysticercosis in Children. ( Thampratankul, L; Veeravigrom, M, 2022) |
| "Albendazole (ABZ) has been used together with praziquantel (PZQ) before for geohelminths, echinococcosis and cysticercosis, but their combined use is not yet formally recommended and only scarce, discrepant data exist on their pharmacokinetics when given together." | 2.76 | Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. ( Bonato, PS; Bustos, JA; Garcia, HH; Gilman, RH; Gonzales, I; Gonzalez, AE; Horton, J; Lanchote, VL; Lescano, AG; Pretell, EJ; Saavedra, H; Takayanagui, OM, 2011) |
| "Neurocysticercosis is a common cause of acquired seizure disorder in developing countries, including India." | 2.73 | Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study. ( Banerjee, M; Das, K; Mondal, GP; Mukherjee, BB; Singh, OP, 2007) |
| "Neurocysticercosis is a parasitic infection of the central nervous system by the larval stage of the pork tapeworm and is a common cause of seizures and epilepsy in endemic areas." | 2.72 | Anthelmintics for people with neurocysticercosis. ( Abba, K; Monk, EJM; Ranganathan, LN, 2021) |
| "Twenty-three patients had seizure recurrence while on antiepilepsy drugs: 36." | 2.71 | Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis. ( Jain, V; Khandelwal, N; Singhi, P, 2004) |
| " There was a good response to levodopa therapy as well as cysticidal therapy with albendazole, allowing later reduction of levodopa dosage in one patient and complete withdrawal in the other." | 2.71 | Parkinsonism associated with neurocysticercosis. ( Sá, DS; Teive, HA; Troiano, AR; Werneck, LC, 2005) |
| " The pharmacokinetic parameters were analyzed by analysis of variance followed by the Tukey-Kramer test." | 2.70 | Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ( Dreossi, SA; Garcia, FS; Lanchote, VL; Takayanagui, OM, 2002) |
| "Seizures were present in 94." | 2.69 | Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. ( Khandelwal, N; Ray, M; Singhi, P; Singhi, S, 2000) |
| "Albendazole was given as a single oral dose of 15 mg per kg body weight (Zentel suspension; Smith Kline & Beecham, Philadelphia, PA)." | 2.68 | Clinical pharmacokinetics of albendazole in children with neurocysticercosis. ( González-Astiazarán, A; González-Esquivel, DF; Jung, H; Martínez, JM; Sánchez, M; Suástegui, R, 1997) |
| "Seizures are the commonest manifestation of brain parenchymal cysticercosis." | 2.55 | Controversies in the treatment of seizures associated with neurocysticercosis. ( Sharma, R; Singh, G, 2017) |
| "Neurocysticercosis is the most common parasitic infection of the brain." | 2.50 | Neurocysticercosis in Wisconsin: 3 cases and a review of the literature. ( Naddaf, E; Seeger, SK; Stafstrom, CE, 2014) |
| "Neurocysticercosis is an infection of the central nervous system by the larval stage of Taenia solium." | 2.49 | Corticosteroids for neurocysticercosis: a systematic review and meta-analysis of randomized controlled trials. ( Cuello-García, CA; Pérez-Gaxiola, G; Roldán-Benítez, YM; Villarreal-Careaga, J, 2013) |
| "Human neurocysticercosis is a severe disease caused by the installation of Taenia solium larvae in the CNS." | 2.48 | Pharmacokinetic variability of anthelmintics: implications for the treatment of neurocysticercosis. ( Jung-Cook, H, 2012) |
| "Neurocysticercosis is an infection of the brain by the larval stage of the pork tapeworm." | 2.46 | Anthelmintics for people with neurocysticercosis. ( Abba, K; Ramaratnam, S; Ranganathan, LN, 2010) |
| "Neurocysticercosis is an infection of the brain by the larval stage of the pork tapeworm." | 2.46 | Anthelmintics for people with neurocysticercosis. ( Abba, K; Ramaratnam, S; Ranganathan, LN, 2010) |
| "Neurocysticercosis is a pleomorphic disease due to individual differences in the number and location of the parasites within the nervous system as well as to differences in the severity of the host's immune reaction against the parasite." | 2.43 | [Neurocysticercosis: up-dating in diagnosis and treatment]. ( Del Brutto, OH, 2005) |
| "55%; P = 0." | 2.43 | Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. ( Coffey, CS; Del Brutto, OH; García, HH; Roos, KL, 2006) |
| "All patients presented with hydrocephalus and/or meningitis." | 2.41 | Intraventricular neurocysticercosis: 18 consecutive patients and review of the literature. ( Andrews, RJ; Cuetter, AC, 2002) |
| "Neurocysticercosis is the most common parasitic disease of the central nervous system." | 2.41 | [A case report of mixed, parenchymatous and meningo-basal neurocysticercosis]. ( de la Peña Elías, C; Higes Pascual, F, 2000) |
| "Albendazole treatment leads to a remarkable reduction in neurocysticercosis lesions throughout the body." | 1.91 | Value of whole-body MRI for the assessment of response to albendazole in disseminated neurocysticercosis: a prospective follow-up study. ( Garg, RK; Jain, A; Kumar, N; Malhotra, HS; Malhotra, KP; Pandey, S; Parihar, A; Rizvi, I; Sharma, PK; Uniyal, R; Verma, R; Wangda, K, 2023) |
| "Oxfendazole (OXF) is an albendazole derivative with efficacy against tissue cestodes of veterinary importance." | 1.72 | Oxfendazole induces protein catabolism and gluconeogenesis in experimental neurocysticercosis. ( Correia, LTB; Costa, TL; de Lima, NF; De Sousa Guerra, CH; Gomes, TC; Vinaud, MC, 2022) |
| " Conclusion: Praziquantel is effective and safe in the treatment of patients with neurocysticercosis." | 1.72 | Efficacy and safety of praziquantel in the treatment of neurocysticercosis in Vietnam. ( Loi, CB; Phuc, TQ; Thang, TD; Thanh, DT; Thieu, NQ; Tho, TH; Tran-Anh, L, 2022) |
| "Cysticercosis is a parasitic tissue infection caused by larval cysts of Taenia solium." | 1.72 | [A Histopathologically Diagnosed Neurocysticercosis Case from Türkiye]. ( Akbulut, A; Akgün, B; Balgetir, F; Çalık, M; Enez, M; Özer Balin, Ş; Yıldırım, H, 2022) |
| "Neurocysticercosis is a major cause of acquired epilepsy." | 1.62 | Frequency and Determinant Factors for Calcification in Neurocysticercosis. ( Arroyo, G; Bustos, JA; Del Brutto, OH; Garcia, HH; Gilman, RH; Gonzales, I; Gonzalez, AE; Nash, TE; O'Neal, SE; Pretell, EJ; Saavedra, H; Soto-Becerra, P, 2021) |
| " Therapeutic failures attributed to medical management of neurocysticercosis with albendazole (ABZ) have been primarily linked to the poor drug absorption rate resulting in low drug level in plasma and brain tissue." | 1.56 | Do albendazole-loaded lipid nanocapsules enhance the bioavailability of albendazole in the brain of healthy mice? ( Benoit, JP; Elissondo, MC; Espinosa, JP; Fabbri, J; Gamboa, GU; Medici, SK; Pensel, PE, 2020) |
| "Nitazoxanide (NTZ) is a broad-spectrum drug used in intestinal infections, but still poorly explored in the treatment of parasitic tissular infections." | 1.56 | In vitro nitazoxanide exposure affects energetic metabolism of Taenia crassiceps. ( Alves, DSMM; Costa, TL; Fraga, CM; Isac, E; Lima, NF; Lino Junior, RS; Picanço, GA; Vinaud, MC, 2020) |
| "Albendazole was administered at a dose of 15 mg/kg/day in 3 cycles of 28 days each." | 1.56 | Quantitative assessment of lesion load and efficacy of 3 cycles of albendazole in disseminated cysticercosis: a prospective evaluation. ( Garg, RK; Jain, A; Kohli, N; Kumar, N; Malhotra, HS; Malhotra, KP; Pandey, S; Rizvi, I; Sharma, P; Uniyal, R; Verma, R, 2020) |
| "Cysticercosis is a neglected tropical disease set as health priority by WHO." | 1.56 | [Disseminated cysticercosis affecting the brain, the eye and the skin on a Senegalese patient]. ( Diallo, K; Diallo, M; Dione, MAD; Diop, A; Manga, NM; Wembulua, BS, 2020) |
| "A case of hemiparesis on left side of body in a young hitherto healthy seafarer which was later diagnosed as a case of neurocysticercosis is described." | 1.56 | A case of neurocysticercosis with an unusual presentation on high seas. ( Kulkarni, AC, 2020) |
| "Ocular cysticercosis is a disease which rarely involves cutaneous skin and the optic nerve." | 1.51 | Disseminated neurocysticercosis with bilateral papilledema: a case report. ( Shrestha, AK; Shrestha, R, 2019) |
| "Neurocysticercosis is the most common parasitic disease of the nervous system, nevertheless, it can remain undetected for a long period of time, especially if it occurs in non endemic areas and regions with low-endemicity." | 1.51 | Long-lasting undetected neurocysticercosis. ( Kostić, A; Kostić, J; Miladinović-Tasić, N; Nikolov, V; Pavlović, M; Stojanović, N; Vidović, N, 2019) |
| "Extraparenchymal neurocysticercosis is the most severe form of cysticercosis, and response to treatment is suboptimal." | 1.51 | Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis. ( Carrillo-Mezo, R; Fleury, A; González-Hernández, I; Jung, H; Matus, C; Osorio, R; Romo, ML; Toledo, A, 2019) |
| "Seizures were the most common presenting symptom in 88." | 1.46 | Time trend of neurocysticercosis in children with seizures in a tertiary hospital of western Nepal. ( Adhikari, S; B K, G; Bahadur, N; Basnet, S; Gauchan, E; Mishra, R; Rao, KS; Sathian, B; Tiwari, PK, 2017) |
| "The onset of anthelmintic treatment of neurocysticercosis (NCC) provokes an acute immune response of the host, which in human cases is associated with exacerbation of neurological symptoms." | 1.46 | Radiological evolution of porcine neurocysticercosis after combined antiparasitic treatment with praziquantel and albendazole. ( Arroyo, G; Bustos, JA; Calcina, J; Cangalaya, C; Chacaltana, J; García, HH; Gonzalez, AE; Guerra-Giraldez, C; Mahanty, S; Mamani, J; Nash, TE; Suarez, D; Vargas-Calla, A, 2017) |
| "Outcome was evaluated in terms of seizure recurrence and resolution of lesions on neuroimaging." | 1.46 | Long-term Clinical and Radiologic Outcome in 500 Children With Parenchymal Neurocysticercosis. ( Deo, B; Khandelwal, NK; Malhi, P; Singhi, P; Suthar, R, 2017) |
| "Albendazole has better therapeutic effects than praziquantel." | 1.43 | [Clinical Analysis of 94 Patients with Neurocysticercosis in Sichuan Province]. ( Hu, TY; Liu, Y; Lv, XJ; Zhong, CJ, 2016) |
| "Neurocysticercosis is a leading cause of acquired epilepsy worldwide and endemic in underdeveloped and developing regions." | 1.42 | [Neurocysticercosis]. ( Burghaus, L; Fink, GR; Gottschalk, A; Meyding-Lamadé, U; Tscherpel, C, 2015) |
| "Taenia solium cysticercosis is a common parasitic infection of humans and pigs." | 1.42 | Successful Antiparasitic Treatment for Cysticercosis is Associated with a Fast and Marked Reduction of Circulating Antigen Levels in a Naturally Infected Pig Model. ( Bustos, JA; Castillo, Y; Dorny, P; Gabriël, S; Garcia, HH; Gilman, RH; Gonzalez, AE; Praet, N; Rodriguez, S; Zimic, M, 2015) |
| "Seizures are the primary clinical manifestation which could be acute (secondary to active lesions) or remote symptomatic (due to calcified lesions)." | 1.40 | Seizure and radiological outcomes in children with solitary cysticercous granulomas with and without albendazole therapy: a retrospective case record analysis. ( Chakrabarty, B; Gulati, S; Gupta, AK; Jain, P; Kumar, A; Pandey, RM; Sachan, D, 2014) |
| "When cerebral cysticercosis were in acute stage (the single and multiple sacculus type, encephalitis type, and macrocyst and sacculus coexistence type), the therapeutic effect was good; while in the mixed type, the therapeutic effect was relatively poor." | 1.40 | [Comparative study on EEG and neuroimaging of patients with cerebral cysticercosis before and after treatment]. ( Fu, TX; Hu, YX; Li, GL; Mao, DH; Tan, WB; Wang, ZL, 2014) |
| "Cysticercosis is a common tropical disease." | 1.38 | Herculean appearance due to disseminated cysticercosis: case report. ( Jain, S; Kashikar, S; Kumar, S, 2012) |
| "Neurocysticercosis is the most common parasitic infection of the central nervous system." | 1.37 | Neurocysticercosis in Qatari patients: case reports. ( Imam, YZ; Kamel, H; Khan, FY; Shafaee, M, 2011) |
| "Neurocysticercosis was easy to misdiagnose." | 1.35 | Clinical analysis of 52 cases of neurocysticercosis. ( Chaoshuang, L; Xiaohong, W; Zhanlian, H; Zhiliang, G; Zhixin, Z, 2008) |
| "Neurocysticercosis is the most common parasitic disease of the central nervous system." | 1.35 | [Degenerating neurocysticercosis cysts: differential diagnosis with cerebral metastasis]. ( Bouvier, C; Coulibaly, B; Fuentes, S; Gautier, G; Ranque, S, 2008) |
| "We report a case of NCC revealed by a Wallenberg's syndrome." | 1.35 | [Wallenberg syndrome and neurocysticercosis: about one case in Ouagadougou, Burkina Faso]. ( Diallo, O; Kabore, J; Kapto, O; Napon, C; Ouédraogo, D, 2009) |
| "Neurocysticercosis is the most common parasitic infestation of the central nervous system, which manifests commonly as acute-onset focal seizures." | 1.35 | Sudden-onset ptosis caused by midbrain neurocysticercosis in 2 children. ( Khandelwal, NK; Mahajan, V; Singhi, P, 2008) |
| "Human cysticercosis is caused by dissemination of embryos of Taenia solium from the intestine via the hepatoportal system to the tissues and organs of the body." | 1.33 | Disseminated cysticercosis involving orbit, brain and subcutaneous tissue. ( Bajaj, MS; Balasubramanya, R; Pushker, N, 2005) |
| "Neurocysticercosis is the most common parasitic infestation of the central nervous system which manifests commonly as acute onset focal seizures." | 1.33 | A rare presentation of neurocysticercosis in a young child. ( Devi, A; Kumar, TS; Moses, PD; Scott, JX, 2005) |
| "Dementia was associated with older age, lower education level, increased number of parasitic lesions in the brain (mostly in the frontal, temporal, and parietal lobes)." | 1.33 | Is dementia reversible in patients with neurocysticercosis? ( Corona, T; Higuera, J; Lopez-Gomez, M; Lopez-Meza, E; Ramirez-Bermudez, J; Sosa, AL, 2005) |
| "Neurocysticercosis is a serious public health problem that predominantly affects places with poor sanitary and hygiene conditions." | 1.33 | [Neurocysticercosis in a State of Piauí urban area: case report]. ( Batista, MS; da Silva Júnior, AN; de Assunção Cordeiro, M; e Silva do Rego Monteiro, AV; Leite, DA; Lima, FC; Lima, RF; Mendes, LC, 2006) |
| "Giant cysts and racemose forms of neurocysticercosis seem to be more frequent in HIV-infected patients and may be secondary to an uncontrolled parasitic growth because of an impaired cell-mediated immune response." | 1.32 | Unusual form of neurocysticercosis associated with HIV infection. ( Couppie, P; Delobel, P; El Guedj, M; Gueye, M; Pradinaud, R; Signate, A; Smadja, D, 2004) |
| "However, recurrence of seizures can be expected in about 15% of patients." | 1.32 | Seizure outcome in patients with a solitary cerebral cysticercus granuloma. ( Jeyaseelan, L; Rajshekhar, V, 2004) |
| "A clinical diagnosis of alexia without agraphia was made and the patient was subjected to routine investigations including contrast MRI." | 1.32 | Transitory alexia without agraphia: a disconnection syndrome due to neurocysticercosis. ( Misra, S; Singh, NN; Verma, A, 2004) |
| "Neurocysticercosis is endemic in certain parts of the world, is rare in Europe and has never previously been described in the Irish healthcare setting." | 1.32 | Neurocysticercosis: a rare cause of seizure. ( Bergin, C; Bonar, M; Cullen, MJ; Merry, C; Ng, V; Nolan, JJ; Smith, D, 2004) |
| "Cysticercosis is an helminthic disease which is usually observed in endemic areas or in immigrants coming from these areas." | 1.32 | [Neurocysticercosis complicating the treatment of cutaneous cysticercosis in a traveller]. ( Bricaire, E; Caumes, E; Chemali, N; Danis, M; Epelboin, L; Klement, E, 2004) |
| "Cerebral cysticercosis is the most common worldwide parasitic infection of the central nervous system." | 1.31 | CSF-VP shunt placement and albendazole therapy for cerebral cysticercosis. ( Mo, L; Pan, X; Shi, Y; Weng, X; Zhu, L, 2002) |
| "Epilepsy is the main revealing symptom." | 1.31 | [Diagnosis of neurocysticercosis: a case report]. ( Andriamamonjy, C; Andriantsimahavandy, A; Rajaonarison, P; Ralamboson, S; Ramanampamonjy, R; Ramanantoanina, CE; Razafindratrimo, F; Villeneuve, R, 2001) |
| "About 65% of cases had recurrences at varying intervals during treatment." | 1.31 | Neurocysticercosis in children: clinical characteristics and outcome. ( Choudhury, V; Popli, VK; Saxena, A; Talukdar, B, 2002) |
| "In Japan neurocysticercosis is a rare disease." | 1.31 | [A case of neurocysticercosis presenting as focal seizure]. ( Higuchi, H; Kobayashi, N; Okada, T; Sugiyama, M; Teramoto, A; Yabe, Y, 2000) |
| "Treatment with albendazole was performed for 21 days, with clinical improvement and seizure remission after 4 months." | 1.31 | Late onset temporal lobe epilepsy with MRI evidence of mesial temporal sclerosis following acute neurocysticercosis: case report. ( Cendes, F; Guerreiro, CA; Kobayashi, E, 2001) |
| "Neurocysticercosis is rarely reported in short-term travelers, although the disease remains a major public health problem in tropical regions." | 1.30 | Neurocysticercosis in an Italian traveler to Latin America. ( Bombana, E; Carosi, G; Chatel, G; El-Hamad, I; Gulletta, M; Matteelli, A; Scolari, C, 1999) |
| "Neurocysticercosis is an infection of the central nervous system with the pork tapeworm's cysticercus." | 1.30 | Neurocysticercosis in pregnancy: a case initially diagnosed as eclampsia. ( Iannucci, TA; Suarez, VR, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (6.09) | 18.2507 |
| 2000's | 121 (43.37) | 29.6817 |
| 2010's | 108 (38.71) | 24.3611 |
| 2020's | 33 (11.83) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, N | 1 |
| Saini, AG | 3 |
| Malhi, P | 2 |
| Khandelwal, N | 8 |
| Singhi, P | 11 |
| Veeravigrom, M | 1 |
| Thampratankul, L | 1 |
| Singh, K | 1 |
| Correia, LTB | 1 |
| de Lima, NF | 3 |
| Gomes, TC | 1 |
| De Sousa Guerra, CH | 2 |
| Costa, TL | 2 |
| Vinaud, MC | 5 |
| Cunningham, FG | 1 |
| Twickler, DM | 1 |
| Takayanagui, OM | 11 |
| Haes, TM | 1 |
| Floß, N | 1 |
| Dolff, S | 1 |
| Junker, A | 1 |
| Blau, T | 1 |
| Rauschenbach, L | 1 |
| Sure, U | 1 |
| Witzke, O | 1 |
| Tappe, D | 1 |
| Schönfeld, A | 1 |
| Thang, TD | 1 |
| Phuc, TQ | 1 |
| Thanh, DT | 1 |
| Thieu, NQ | 1 |
| Tho, TH | 1 |
| Loi, CB | 1 |
| Tran-Anh, L | 1 |
| Wangda, K | 1 |
| Kumar, N | 2 |
| Garg, RK | 5 |
| Malhotra, HS | 3 |
| Rizvi, I | 2 |
| Uniyal, R | 2 |
| Pandey, S | 3 |
| Malhotra, KP | 2 |
| Verma, R | 6 |
| Sharma, PK | 1 |
| Parihar, A | 1 |
| Jain, A | 2 |
| Singla, A | 1 |
| Lekhwani, S | 1 |
| Vaswani, ND | 2 |
| Kaushik, JS | 3 |
| Dabla, S | 1 |
| Özer Balin, Ş | 3 |
| Enez, M | 3 |
| Akbulut, A | 3 |
| Çalık, M | 3 |
| Akgün, B | 3 |
| Balgetir, F | 3 |
| Yıldırım, H | 3 |
| Garg, D | 3 |
| Sharma, S | 2 |
| Tao, B | 1 |
| Li, T | 1 |
| Ji, K | 1 |
| Shang, A | 1 |
| Stelzle, D | 1 |
| Makasi, C | 1 |
| Schmidt, V | 1 |
| Trevisan, C | 1 |
| Van Damme, I | 1 |
| Ruether, C | 1 |
| Dorny, P | 4 |
| Magnussen, P | 1 |
| Zulu, G | 1 |
| Mwape, KE | 1 |
| Bottieau, E | 1 |
| Prazeres da Costa, C | 1 |
| Prodjinotho, UF | 1 |
| Carabin, H | 1 |
| Jackson, E | 1 |
| Fleury, A | 4 |
| Gabriël, S | 2 |
| Ngowi, BJ | 1 |
| Winkler, AS | 1 |
| Kleebayoon, A | 2 |
| Wiwanitkit, V | 1 |
| da Silva Santana, RC | 1 |
| Prudente, TP | 1 |
| de Souza Lino Junior, R | 1 |
| Nazish, S | 1 |
| Almuhanna, M | 1 |
| Montgomery, MA | 1 |
| Ramos, M | 1 |
| Kelvin, EA | 6 |
| Carpio, A | 7 |
| Jaramillo, A | 2 |
| Hauser, WA | 5 |
| Zhang, H | 2 |
| Shrestha, R | 1 |
| Shrestha, AK | 1 |
| Fabbri, J | 1 |
| Espinosa, JP | 1 |
| Pensel, PE | 1 |
| Medici, SK | 1 |
| Gamboa, GU | 1 |
| Benoit, JP | 1 |
| Elissondo, MC | 1 |
| Nash, TE | 7 |
| O'Connell, EM | 1 |
| Hammoud, DA | 1 |
| Wetzler, L | 1 |
| Ware, JM | 2 |
| Mahanty, S | 4 |
| Francisca, PA | 1 |
| Javier, LF | 1 |
| Guadalupe, PH | 1 |
| Fernanda, GM | 1 |
| Nelly, C | 1 |
| Helgi, JC | 1 |
| Iliana, GH | 1 |
| Susana, RI | 1 |
| Isac, E | 1 |
| Picanço, GA | 2 |
| Lima, NF | 1 |
| Alves, DSMM | 1 |
| Fraga, CM | 2 |
| Lino Junior, RS | 2 |
| Kostić, A | 1 |
| Vidović, N | 1 |
| Miladinović-Tasić, N | 1 |
| Kostić, J | 1 |
| Nikolov, V | 1 |
| Stojanović, N | 1 |
| Pavlović, M | 1 |
| Kohli, N | 2 |
| Sharma, P | 1 |
| Barrie, U | 1 |
| Badejo, O | 1 |
| Aoun, SG | 1 |
| Adeyemo, E | 1 |
| Moler, N | 1 |
| Christian, ZK | 1 |
| Caruso, JP | 1 |
| El Ahmadieh, TY | 1 |
| Ban, VS | 1 |
| MacAllister, MC | 1 |
| Reyes, VP | 1 |
| Hall, K | 1 |
| Whitworth, L | 1 |
| Bagley, CA | 1 |
| Sampaio, GA | 1 |
| Zago, LV | 1 |
| Del Brutto, OH | 10 |
| Pérez-Jacoiste Asín, MA | 1 |
| Calleja-Castaño, P | 1 |
| Hilario, A | 1 |
| Bustos, JA | 10 |
| Arroyo, G | 3 |
| Gilman, RH | 8 |
| Soto-Becerra, P | 1 |
| Gonzales, I | 6 |
| Saavedra, H | 6 |
| Pretell, EJ | 8 |
| O'Neal, SE | 1 |
| Gonzalez, AE | 7 |
| Garcia, HH | 19 |
| Landzberg, DR | 1 |
| Dhir, A | 1 |
| Jillella, DV | 1 |
| Wembulua, BS | 1 |
| Diallo, K | 1 |
| Diallo, M | 2 |
| Dione, MAD | 1 |
| Diop, A | 1 |
| Manga, NM | 1 |
| Kulkarni, AC | 1 |
| Monk, EJM | 1 |
| Abba, K | 3 |
| Ranganathan, LN | 3 |
| Sankhyan, N | 2 |
| Kadwa, RA | 1 |
| Kamate, M | 1 |
| Kannan, L | 1 |
| Kumar, A | 2 |
| Passi, GR | 1 |
| Sharawat, IK | 1 |
| de Souza, A | 4 |
| Nalini, A | 4 |
| Saini, J | 2 |
| Thennarasu, K | 4 |
| Yadav, K | 1 |
| Dubey, R | 1 |
| Agarwal, S | 1 |
| Yacoub, HA | 1 |
| Goldstein, I | 1 |
| El-Ghanem, M | 1 |
| Sharer, L | 1 |
| Souayah, N | 1 |
| Rao, KS | 1 |
| Adhikari, S | 1 |
| Gauchan, E | 1 |
| Sathian, B | 1 |
| B K, G | 1 |
| Basnet, S | 1 |
| Tiwari, PK | 1 |
| Bahadur, N | 1 |
| Mishra, R | 1 |
| Cangalaya, C | 1 |
| Calcina, J | 1 |
| Vargas-Calla, A | 1 |
| Mamani, J | 1 |
| Suarez, D | 1 |
| Chacaltana, J | 1 |
| Guerra-Giraldez, C | 2 |
| Singh, G | 4 |
| Sharma, R | 1 |
| Muralidharan, V | 1 |
| Nair, BR | 1 |
| Patel, B | 1 |
| Rajshekhar, V | 5 |
| Singh, SK | 1 |
| Prasad, KN | 1 |
| Singh, AK | 1 |
| Gupta, KK | 1 |
| Singh, A | 1 |
| Tripathi, M | 1 |
| Gupta, RK | 2 |
| Ong, SCL | 1 |
| Koh, KC | 1 |
| Mugundhan, K | 1 |
| Balamurugan, N | 1 |
| Chandrasekar, P | 1 |
| Sivakumar, S | 1 |
| Mayan, MCV | 1 |
| Nidhin, PD | 1 |
| Thapa, K | 1 |
| Romo, ML | 6 |
| Leslie, D | 3 |
| Andrews, H | 3 |
| Persichino, JG | 1 |
| Miller, LG | 1 |
| Smith, EA | 1 |
| Marks, G | 1 |
| Hirai-Yang, A | 1 |
| Tran, H | 1 |
| Liu, Y | 1 |
| Hu, TY | 1 |
| Zhong, CJ | 1 |
| Lv, XJ | 1 |
| Osorio, R | 1 |
| Carrillo-Mezo, R | 2 |
| Toledo, A | 1 |
| Matus, C | 1 |
| González-Hernández, I | 2 |
| Jung, H | 4 |
| Ying-Xin, H | 1 |
| Feng-Ju, J | 1 |
| Hua, T | 1 |
| Zhen-Hua, Y | 1 |
| Jun, D | 1 |
| Tao, Y | 1 |
| Coyle, CM | 1 |
| Lescano, AG | 4 |
| Rodriguez, S | 2 |
| Bonato, PS | 5 |
| Lanchote, VL | 8 |
| Horton, J | 3 |
| Villela, VA | 1 |
| Dixon, AM | 1 |
| Steele, R | 1 |
| Chang, M | 1 |
| Baird, RA | 2 |
| Wiebe, S | 2 |
| Zunt, JR | 2 |
| Halperin, JJ | 2 |
| Gronseth, G | 1 |
| Roos, KL | 3 |
| Itani, MM | 1 |
| Jørgensen, GM | 1 |
| Ruiz-Sandoval, JL | 1 |
| Ramírez-Guzmán, G | 1 |
| Chiquete, E | 1 |
| Vargas-Sánchez, Á | 1 |
| Burneo, JG | 3 |
| Escalaya, AL | 1 |
| Taha, H | 1 |
| Das, S | 1 |
| Arauz, A | 1 |
| Ruiz-Navarro, F | 1 |
| Silos, H | 1 |
| Vargas-González, JC | 1 |
| Arguelles-Morales, N | 1 |
| Reyes, M | 1 |
| Ruiz-Franco, A | 1 |
| Rivera, A | 2 |
| Gonzalez-Duarte, A | 1 |
| Sethi, NK | 1 |
| Kim, SW | 1 |
| Wang, HS | 1 |
| Ju, CI | 1 |
| Kim, DM | 1 |
| de Almeida Leandro, L | 1 |
| de Souza Lino, R | 1 |
| Nogales-Gaete, J | 2 |
| Arias-Quezada, P | 1 |
| Jurado-Díaz, F | 1 |
| Min, Z | 1 |
| Gulati, S | 1 |
| Jain, P | 1 |
| Sachan, D | 1 |
| Chakrabarty, B | 1 |
| Pandey, RM | 1 |
| Gupta, AK | 1 |
| Naddaf, E | 1 |
| Seeger, SK | 1 |
| Stafstrom, CE | 1 |
| White, AC | 1 |
| Zimic, M | 2 |
| Escalante, D | 1 |
| Gavidia, M | 2 |
| Rodriguez, L | 2 |
| Najar, E | 2 |
| Umeres, H | 2 |
| Sundaresan, S | 1 |
| Sanklecha, M | 1 |
| Wang, ZL | 1 |
| Fu, TX | 1 |
| Hu, YX | 1 |
| Li, GL | 1 |
| Mao, DH | 1 |
| Tan, WB | 1 |
| Segamwenge, IL | 1 |
| Kioko, NP | 1 |
| Shaigany, S | 1 |
| Dabela, E | 1 |
| Teich, AF | 1 |
| Husain, S | 1 |
| Grossman, ME | 1 |
| Ramos-Zúñiga, R | 2 |
| Pérez-Gómez, HR | 2 |
| Gaytán-Martínez, LA | 1 |
| Vega-Ruiz, B | 1 |
| Soto-Rodríguez, S | 1 |
| Rochín-Mozqueda, A | 1 |
| Chaurasia, RN | 2 |
| Mishra, VN | 1 |
| Jaiswal, S | 1 |
| Mahamat, A | 1 |
| Abboud, P | 1 |
| Demar, M | 1 |
| JeanBourquin, D | 1 |
| Djossou, F | 1 |
| Wang, W | 1 |
| Mouhari-Toure, A | 1 |
| N'Timon, B | 1 |
| Kumako, V | 1 |
| Darre, T | 1 |
| Saka, B | 1 |
| Tchaou, M | 1 |
| Amegbor, K | 1 |
| Kombate, K | 1 |
| Balogou, AA | 1 |
| Pitche, P | 1 |
| Bugeme, M | 1 |
| Mukuku, O | 1 |
| Shinde, RL | 1 |
| Bharkad, GP | 1 |
| Devarajan, PV | 1 |
| Tscherpel, C | 1 |
| Gottschalk, A | 1 |
| Meyding-Lamadé, U | 1 |
| Fink, GR | 1 |
| Burghaus, L | 1 |
| Castillo, Y | 1 |
| Praet, N | 1 |
| Wyka, K | 1 |
| Bagiella, E | 2 |
| Sato, A | 1 |
| Nakamura, I | 1 |
| Fujita, H | 1 |
| Fukushima, S | 1 |
| Mizuno, Y | 1 |
| Fujii, T | 2 |
| Matsumoto, T | 1 |
| Ghasemi, R | 1 |
| Rowe, A | 1 |
| Shah, R | 1 |
| Venkatesan, P | 1 |
| England, TJ | 1 |
| Suthar, R | 1 |
| Deo, B | 1 |
| Khandelwal, NK | 2 |
| Chaoshuang, L | 1 |
| Zhixin, Z | 1 |
| Xiaohong, W | 1 |
| Zhanlian, H | 1 |
| Zhiliang, G | 1 |
| Odermatt, P | 1 |
| Preux, PM | 1 |
| Druet-Cabanac, M | 1 |
| Coulibaly, B | 1 |
| Gautier, G | 1 |
| Fuentes, S | 1 |
| Ranque, S | 1 |
| Bouvier, C | 1 |
| Kasliwal, MK | 1 |
| Gupta, DK | 1 |
| Suri, V | 1 |
| Sharma, BS | 2 |
| Garg, A | 1 |
| Sobnach, S | 1 |
| Khosa, SA | 1 |
| Pather, S | 1 |
| Longhurst, S | 1 |
| Kahn, D | 1 |
| Raubenheimer, PJ | 1 |
| Plener, I | 1 |
| Hajek, J | 1 |
| Keystone, J | 1 |
| Kaur, S | 1 |
| Singhi, S | 2 |
| Ranjith, MP | 1 |
| Divya, R | 1 |
| Sahni, A | 1 |
| Napon, C | 1 |
| Ouédraogo, D | 1 |
| Diallo, O | 1 |
| Kapto, O | 1 |
| Kabore, J | 1 |
| Sohrabi, F | 1 |
| Proaño, JV | 2 |
| Torres-Corzo, J | 1 |
| Rodríguez-Della Vecchia, R | 1 |
| Guizar-Sahagun, G | 1 |
| Rangel-Castilla, L | 1 |
| Remy, S | 1 |
| Asnis, D | 1 |
| Kazakov, J | 1 |
| Toronjadze, T | 1 |
| Bern, C | 1 |
| McAuliffe, I | 1 |
| Bishop, H | 1 |
| Lee, L | 1 |
| Grossmann, R | 1 |
| Garcia, MA | 1 |
| Di John, D | 1 |
| Chhiber, SS | 1 |
| Singh, B | 2 |
| Bansal, P | 1 |
| Pandita, KK | 1 |
| Razdan, S | 1 |
| Singh, J | 1 |
| Castro, N | 1 |
| Márquez-Caraveo, C | 3 |
| Brundage, RC | 1 |
| González-Esquivel, D | 1 |
| Suárez, AM | 1 |
| Góngora, F | 1 |
| Jara, A | 1 |
| Urizar, J | 1 |
| Lanao, JM | 1 |
| Kovoor, JM | 2 |
| Yeshraj, G | 2 |
| Siddalingaiah, HS | 2 |
| Maïga, Y | 1 |
| Bouteille, B | 1 |
| Konate, A | 1 |
| Diarra, M | 1 |
| Maïga, M | 1 |
| Marjolet, M | 1 |
| Goel, D | 1 |
| Mittal, M | 1 |
| Bansal, KK | 1 |
| Singhal, A | 1 |
| Pittayanon, R | 1 |
| Buranasupkajorn, P | 1 |
| Snabboon, T | 1 |
| Ramaratnam, S | 2 |
| Cárdenas, G | 2 |
| Sciutto, E | 1 |
| Hernandez, JL | 1 |
| Agarwall, A | 1 |
| Singh, MK | 5 |
| Shukla, R | 2 |
| Weber, D | 1 |
| Stevens, EA | 1 |
| Couture, DE | 1 |
| Winslow, JE | 1 |
| Okome-Nkoumou, MM | 1 |
| Ondounda, M | 1 |
| Dzeing-Ella, A | 1 |
| Mounguengui, D | 1 |
| Madjinou, MI | 1 |
| Clevenbergh, P | 1 |
| Magne, C | 1 |
| Nzenze, JR | 1 |
| Song, TJ | 1 |
| Suh, SH | 1 |
| Cho, H | 1 |
| Lee, KY | 1 |
| Jivan, K | 1 |
| Mochan, A | 1 |
| Modi, G | 1 |
| Ruiz, S | 1 |
| García-Vázquez, E | 1 |
| Picazo, R | 1 |
| Hernández, A | 1 |
| Herrero, JA | 1 |
| Gómez, J | 1 |
| Sundar, U | 1 |
| Chawla, V | 1 |
| Lakkas, Y | 1 |
| Shrivastava, M | 1 |
| Asole, D | 1 |
| Vaidy, M | 1 |
| Karnik, PS | 1 |
| Tullu, MS | 1 |
| David, JJ | 1 |
| Ghildiyal, RG | 1 |
| Ruiz-Olmedo, MI | 1 |
| Jung-Cook, H | 2 |
| Eakle, DL | 1 |
| Wright, WF | 1 |
| Khan, FY | 1 |
| Imam, YZ | 2 |
| Kamel, H | 1 |
| Shafaee, M | 1 |
| Ooi, WW | 1 |
| Wijemanne, S | 1 |
| Thomas, CB | 1 |
| Quezado, M | 1 |
| Brown, CR | 1 |
| Odashima, NS | 1 |
| Lima, JE | 1 |
| Kaushal, S | 1 |
| Sharma, A | 1 |
| Kumar, V | 2 |
| Sharma, V | 1 |
| Chandramohan, R | 1 |
| Kadhiravan, T | 1 |
| Swaminathan, RP | 1 |
| Khurana, N | 1 |
| Jáuregui-Huerta, F | 1 |
| del Sol López-Hernández, M | 1 |
| Valera-Lizárraga, JE | 1 |
| Paz-Vélez, G | 1 |
| Becerra-Valdivia, A | 1 |
| Prasad, R | 3 |
| Kapoor, K | 1 |
| Mishra, D | 1 |
| Srivastava, A | 1 |
| Mishra, OP | 2 |
| Azzopardi, L | 1 |
| Quirk, J | 1 |
| Shin, SH | 1 |
| Hwang, BW | 1 |
| Lee, SJ | 1 |
| Lee, SH | 1 |
| Maeda, T | 1 |
| Ito, A | 1 |
| Sako, Y | 1 |
| Yamasaki, H | 1 |
| Oyaizu, N | 1 |
| Odawara, T | 1 |
| Iwamoto, A | 1 |
| Thakur, N | 1 |
| Mohanty, C | 1 |
| Singh, UK | 1 |
| Naphade, PU | 1 |
| Rai, D | 1 |
| Mesraoua, B | 1 |
| Deleu, D | 1 |
| D'souza, A | 1 |
| Melikyan, G | 1 |
| Sanjay, S | 1 |
| Koh, YT | 1 |
| Gan, NY | 1 |
| Kumar, S | 2 |
| Jain, S | 1 |
| Kashikar, S | 1 |
| Paredes, A | 1 |
| de Campos Lourenço, T | 1 |
| Marzal, M | 1 |
| Cass, QB | 1 |
| Otte, WM | 1 |
| Singla, M | 1 |
| Sander, JW | 2 |
| Cuello-García, CA | 1 |
| Roldán-Benítez, YM | 1 |
| Pérez-Gaxiola, G | 1 |
| Villarreal-Careaga, J | 1 |
| Jaiswal, A | 1 |
| Dournon, N | 1 |
| Epelboin, L | 2 |
| Brion, MC | 1 |
| Paris, L | 1 |
| Bricaire, F | 1 |
| Caumes, E | 2 |
| Sharma, K | 1 |
| Wahi, J | 1 |
| Phadke, RV | 1 |
| Varma, A | 1 |
| Jain, VK | 2 |
| Zhu, L | 2 |
| Weng, X | 2 |
| Shi, Y | 2 |
| Pan, X | 2 |
| Mo, L | 2 |
| Dreossi, SA | 2 |
| Pretell, J | 1 |
| Rajaonarison, P | 1 |
| Ralamboson, S | 1 |
| Andriamamonjy, C | 1 |
| Ramanampamonjy, R | 1 |
| Ramanantoanina, CE | 1 |
| Razafindratrimo, F | 1 |
| Villeneuve, R | 1 |
| Andriantsimahavandy, A | 1 |
| Talukdar, B | 1 |
| Saxena, A | 1 |
| Popli, VK | 1 |
| Choudhury, V | 1 |
| Zhao, S | 1 |
| Xu, K | 1 |
| Dayal, D | 1 |
| Zoli, AP | 1 |
| Ongolo-Zogo, P | 1 |
| Brandt, J | 1 |
| Geerts, S | 1 |
| Keiser, PB | 1 |
| Narula, G | 1 |
| Bawa, KS | 1 |
| Kalra, V | 1 |
| Dua, T | 1 |
| Guo, DM | 1 |
| Xie, SP | 1 |
| Jia, JP | 1 |
| Delobel, P | 1 |
| Signate, A | 1 |
| El Guedj, M | 1 |
| Couppie, P | 1 |
| Gueye, M | 1 |
| Smadja, D | 1 |
| Pradinaud, R | 1 |
| Maguire, JH | 1 |
| Martinez, SM | 1 |
| Moulton, LH | 1 |
| Herrera, G | 1 |
| Evans, CA | 1 |
| Sotelo, J | 1 |
| Bowie, EM | 1 |
| Folk, JC | 1 |
| Barnes, CH | 1 |
| van der Meer, P | 1 |
| Quant-Durán, C | 1 |
| Sabbatani, S | 2 |
| Fasulo, G | 1 |
| Chiodo, F | 2 |
| Ortega-Herrera, R | 1 |
| Fernández-Segura, ME | 1 |
| Gómez de Travecedo Y Calvo, I | 1 |
| Rojas-Flores, I | 1 |
| Sodhi, PK | 1 |
| Ratan, SK | 1 |
| Góngora-Rivera, F | 2 |
| Santos Zambrano, J | 1 |
| Hernández, R | 1 |
| Soto-Hernández, JL | 2 |
| Jeyaseelan, L | 1 |
| Jain, V | 1 |
| Singh, P | 1 |
| Sahai, K | 1 |
| Mateus, FH | 1 |
| Verma, A | 1 |
| Singh, NN | 1 |
| Misra, S | 1 |
| Honorato, D | 1 |
| Borges, W | 1 |
| Vargas, AA | 1 |
| Ramina, R | 1 |
| Castillo, M | 1 |
| Smith, D | 1 |
| Ng, V | 1 |
| Bonar, M | 1 |
| Merry, C | 1 |
| Bergin, C | 1 |
| Cullen, MJ | 1 |
| Nolan, JJ | 1 |
| Yuan, Z | 1 |
| Ren, HJ | 1 |
| Ding, YZ | 1 |
| Zhang, JS | 1 |
| Wang, WP | 1 |
| Wu, XL | 1 |
| Qiu, MD | 1 |
| Sá, DS | 1 |
| Teive, HA | 1 |
| Troiano, AR | 1 |
| Werneck, LC | 1 |
| Zucchelli, M | 1 |
| Calbucci, F | 1 |
| Roncaroli, F | 1 |
| Im, SH | 1 |
| Park, SH | 1 |
| Oh, DH | 1 |
| Kang, BS | 1 |
| Kwon, OK | 1 |
| Oh, CW | 1 |
| Besada, E | 1 |
| Barr, R | 1 |
| Natu, A | 1 |
| Pushker, N | 2 |
| Bajaj, MS | 2 |
| Balasubramanya, R | 1 |
| Cuetter, AC | 1 |
| Andrews, RJ | 1 |
| Schlaen, BR | 1 |
| Asad, S | 1 |
| Neill, MA | 1 |
| Scott, JX | 1 |
| Devi, A | 1 |
| Kumar, TS | 1 |
| Moses, PD | 1 |
| Ramirez-Bermudez, J | 1 |
| Higuera, J | 1 |
| Sosa, AL | 1 |
| Lopez-Meza, E | 1 |
| Lopez-Gomez, M | 1 |
| Corona, T | 1 |
| Singh, R | 1 |
| Joshi, B | 1 |
| Castillo-Iglesias, H | 1 |
| Mouly, S | 1 |
| Ducros, A | 1 |
| Sarfati, C | 1 |
| Sulahian, A | 1 |
| Bergmann, JF | 1 |
| Guo, CY | 1 |
| Yang, HM | 1 |
| Ma, GR | 1 |
| González Esquivel, D | 1 |
| Cook, HJ | 1 |
| Hernández Dávila, R | 1 |
| Santos-Zambrano, J | 1 |
| Llanos-Zavalaga, F | 1 |
| Hoare, M | 1 |
| Gelson, WT | 1 |
| Antoun, N | 1 |
| Alexander, GJ | 1 |
| Menon, B | 1 |
| Arasu, K | 1 |
| Khairul, A | 1 |
| Waran, V | 1 |
| Alarcón, F | 1 |
| Maldonado, JC | 1 |
| Costa, CU | 1 |
| von Einsiedel, HG | 1 |
| Disko, R | 1 |
| Berthele, A | 1 |
| Chotmongkol, V | 1 |
| Sawanyawisuth, K | 1 |
| Limpawattana, P | 1 |
| Phuphatham, A | 1 |
| Chotmongkol, R | 1 |
| Intapan, PM | 1 |
| e Silva do Rego Monteiro, AV | 1 |
| da Silva Júnior, AN | 1 |
| Leite, DA | 1 |
| Mendes, LC | 1 |
| de Assunção Cordeiro, M | 1 |
| Lima, RF | 1 |
| Lima, FC | 1 |
| Batista, MS | 1 |
| Coffey, CS | 1 |
| Gerber, JS | 1 |
| Shah, SS | 1 |
| Arriagada, C | 1 |
| Salinas, R | 4 |
| Bruschi, F | 1 |
| Giangaspero, F | 1 |
| Castagna, M | 1 |
| Becherini, F | 1 |
| Filice, ME | 1 |
| Vannozzi, R | 1 |
| Cantini, R | 1 |
| Ahmad, FU | 1 |
| Agarwal, A | 1 |
| Kar, AM | 1 |
| Klement, E | 1 |
| Chemali, N | 1 |
| Danis, M | 1 |
| Bricaire, E | 1 |
| Gonzalez, I | 1 |
| Mija, L | 1 |
| Mazumdar, M | 1 |
| Pandharipande, P | 1 |
| Poduri, A | 1 |
| Prasad, K | 3 |
| Jethani, J | 1 |
| Vijayalakshmi, P | 1 |
| Kumar, M | 1 |
| Bergroth, B | 1 |
| Contardo, DM | 1 |
| Mazzei, ME | 1 |
| Abuchanab, ME | 1 |
| Melero, MJ | 1 |
| Thussu, A | 2 |
| Chattopadhyay, A | 1 |
| Sawhney, IM | 2 |
| Das, K | 1 |
| Mondal, GP | 1 |
| Banerjee, M | 1 |
| Mukherjee, BB | 1 |
| Singh, OP | 1 |
| Husain, N | 1 |
| Shukla, N | 1 |
| Kumar, R | 1 |
| Husain, M | 1 |
| Chaturvedi, A | 1 |
| Agarwal, GG | 1 |
| Chakraborty, PP | 1 |
| Bhattacharjee, R | 1 |
| Chatterjee, K | 1 |
| Mahajan, V | 1 |
| Matthaiou, DK | 1 |
| Panos, G | 1 |
| Adamidi, ES | 1 |
| Falagas, ME | 1 |
| Montoya, E | 1 |
| Katabarwa, M | 1 |
| Lakwo, T | 1 |
| Habumogisha, P | 1 |
| Richards, F | 1 |
| Eberhard, M | 1 |
| Rocha, MA | 2 |
| Santos, JM | 1 |
| Gomes, EC | 1 |
| Rocha, CF | 1 |
| Carvalho, GT | 1 |
| Costa, BS | 1 |
| Vera de Pedro, E | 1 |
| Vereas Martínez, A | 1 |
| Pilar Orive, J | 1 |
| López Fernández, Y | 1 |
| Morteruel Arizkuren, E | 1 |
| Leon, P | 1 |
| Baranwal, AK | 1 |
| Singhi, PD | 2 |
| Singhi, SC | 1 |
| Agapejev, S | 2 |
| Yela, DA | 1 |
| Gomes, AE | 1 |
| Chatel, G | 1 |
| Gulletta, M | 1 |
| Scolari, C | 1 |
| Bombana, E | 1 |
| El-Hamad, I | 1 |
| Matteelli, A | 1 |
| Carosi, G | 1 |
| Marques, MP | 2 |
| Santos, SR | 1 |
| Campos, X | 1 |
| Sánchez, J | 1 |
| Mosquera, A | 1 |
| Isozumi, K | 1 |
| Izumi, Y | 1 |
| Sánchez, M | 1 |
| González-Astiazarán, A | 1 |
| Martínez, JM | 1 |
| Suástegui, R | 1 |
| González-Esquivel, DF | 1 |
| Ray, M | 2 |
| Monteiro, L | 1 |
| Lopes, J | 1 |
| Martins da Silva, A | 1 |
| Counsell, C | 1 |
| Gelband, H | 1 |
| Garner, P | 1 |
| Kim, SK | 1 |
| Wang, KC | 1 |
| Paek, SH | 1 |
| Hong, KS | 1 |
| Cho, BK | 1 |
| Gupta, S | 2 |
| Sen, J | 1 |
| Arora, B | 1 |
| Zardi, EM | 1 |
| Petrarca, V | 1 |
| Pozio, E | 1 |
| Uwechie, V | 1 |
| Tamburrini, A | 1 |
| Laghi, V | 1 |
| Shahid, SK | 1 |
| Morales, NM | 1 |
| Morales, RR | 1 |
| Padula, NA | 1 |
| Lima, MM | 1 |
| Higes Pascual, F | 1 |
| de la Peña Elías, C | 1 |
| Djientcheu, VD | 1 |
| Zona, G | 1 |
| Rilliet, B | 1 |
| Suarez, VR | 1 |
| Iannucci, TA | 1 |
| Huang, PP | 1 |
| Choudhri, HF | 1 |
| Jallo, G | 1 |
| Miller, DC | 1 |
| Gogna, A | 1 |
| Sugiyama, M | 1 |
| Okada, T | 1 |
| Higuchi, H | 1 |
| Yabe, Y | 1 |
| Kobayashi, N | 1 |
| Teramoto, A | 1 |
| Senel, A | 1 |
| Cokluk, C | 1 |
| Yildiz, L | 1 |
| Ağar, E | 1 |
| Ayyildiz, M | 1 |
| Onder, A | 1 |
| Santos, IC | 1 |
| Kobayashi, E | 2 |
| Cardoso, TM | 1 |
| Guerreiro, CA | 2 |
| Cendes, F | 2 |
| Biswas, A | 1 |
| Prasad, A | 1 |
| Anand, KS | 1 |
| Cicalini, S | 1 |
| Escriba, D | 1 |
| Francavilla, R | 1 |
| De Rosa, FG | 1 |
| Arora, A | 1 |
| Lal, V | 1 |
| Prabhakar, S | 1 |
| Chandra, M | 1 |
| Madrazo, I | 1 |
| Avelar, F | 1 |
| López-Félix, B | 1 |
| Díaz, G | 1 |
| Grijalva, I | 1 |
| Gulliani, BP | 1 |
| Dadeya, S | 1 |
| Malik, KP | 1 |
| Jain, DC | 1 |
| Garcia, FS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Characteristics of Patients With Symptomatic Active Neurocysticercosis and Effect of Treatment on Symptoms, Lesions and Quality of Life in Resource-poor Rural Areas of Eastern Africa - TOPANA, a Multi-centre Prospective Cohort Study.[NCT03834337] | 63 participants (Actual) | Observational | 2019-04-01 | Completed | |||
| Clinical, Laboratory and Imaging Features, Treatment Trends and Long Term Outcomes in Patients With Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study[NCT04706819] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2021-01-15 | Not yet recruiting | |||
| Antiparasitic Therapy for Neurocysticercosis: Phase II/III Study on Safety and Efficacy of Combined Treatment With Praziquantel and Albendazole[NCT00441285] | Phase 2/Phase 3 | 156 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Pilot Study of Neurocysticercosis Treatment[NCT00283699] | Phase 3 | 178 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Proportion of patients whose 6 month MR does not show viable parasites anymore (NCT00441285)
Timeframe: Day 180
| Intervention | participants (Number) |
|---|---|
| Phase III Trial - ABZ+PZQ | 25 |
| Phase III Trial - Increased ABZ | 19 |
| Phase III Trial - Standard ABZ | 15 |
- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel). (NCT00441285)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on Treatment days 10-11
| Intervention | ng*h/ml (Mean) |
|---|---|
| Albendazole + Praziquantel | 4925.3 |
| Albendazole + Placebo | 2969.6 |
- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel). (NCT00441285)
Timeframe: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose on Treatment day 1
| Intervention | ng*h/mL (Mean) |
|---|---|
| Albendazole + Praziquantel | 1412.2 |
| Albendazole + Placebo | 1111 |
- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin (NCT00441285)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on treatment days 10-11
| Intervention | ng*h/ml (Mean) |
|---|---|
| Carbamazepine | 240.2 |
| Phenytoin | 550.1 |
Highest serum level of Albendazole measured from all level assessments in the curve. (NCT00441285)
Timeframe: Treatment day 1 and Treatment days 10-11
| Intervention | ng/mL (Mean) |
|---|---|
| Albendazole + Praziquantel | 1293.9 |
| Albendazole + Placebo | 2232.8 |
- Describe if some Serious Adverse Event was associated to combined Albendazole plus Praziquantel therapy. (NCT00441285)
Timeframe: 90 days post tx
| Intervention | Events (Number) |
|---|---|
| Albendazole + Praziquantel | 0 |
| Albendazole + Placebo | 0 |
- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin (NCT00441285)
Timeframe: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose in treatment day 1
| Intervention | ng*h / mL (Mean) | |
|---|---|---|
| Carbamazepine (n=8) | Phenytoin (n=8) | |
| Albendazole + Praziquantel | 548.3 | 923.7 |
39 reviews available for albendazole and Central Nervous System Cysticercosis
| Article | Year |
|---|---|
Neurocysticercosis in Children.
Topics: Adolescent; Albendazole; Animals; Anticonvulsants; Antiprotozoal Agents; Blindness; Child; Child, Pr | 2022 |
Update on the diagnosis and management of neurocysticercosis.
Topics: Albendazole; Epilepsy; Humans; Magnetic Resonance Imaging; Neurocysticercosis; Praziquantel | 2022 |
Spinal nerve root sleeve cysticercosis: a case report and review of the literature.
Topics: Albendazole; Arachnoid Cysts; Cysticercosis; Female; Humans; Magnetic Resonance Imaging; Middle Aged | 2023 |
Systematic Review and Meta-Analysis of Management Strategies and Outcomes in Adult Spinal Neurocysticercosis.
Topics: Adrenal Cortex Hormones; Adult; Aged; Albendazole; Animals; Anticestodal Agents; Combined Modality T | 2020 |
Current approaches to cysticidal drug therapy for neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Brain; Cysticercus; Drug Therapy, Combination; Humans; Neurocys | 2020 |
Anthelmintics for people with neurocysticercosis.
Topics: Adult; Albendazole; Anticestodal Agents; Bias; Brain Diseases; Child; Humans; Neurocysticercosis; Pl | 2021 |
Antiparasitic treatment of neurocysticercosis - The effect of cyst destruction in seizure evolution.
Topics: Albendazole; Anticestodal Agents; Antiparasitic Agents; Brain; Cysts; Epilepsy; Female; Humans; Infl | 2017 |
Controversies in the treatment of seizures associated with neurocysticercosis.
Topics: Adrenal Cortex Hormones; Albendazole; Anticonvulsants; Choice Behavior; Consensus; Epilepsy; Granulo | 2017 |
[Changes of brain CT imaging of cerebral cysticercosis patients during the period of anti-cysticercus chemotherapy].
Topics: Albendazole; Animals; Brain; Cysticercus; Humans; Neurocysticercosis; Tomography, X-Ray Computed | 2018 |
Neurocysticercosis.
Topics: Albendazole; Anthelmintics; Humans; Neurocysticercosis; Praziquantel | 2013 |
Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: a reason for the variable efficacy of albendazole and praziquantel?
Topics: Adrenal Cortex Hormones; Albendazole; Animals; Anthelmintics; Anticonvulsants; Drug Interactions; Hi | 2014 |
Neurocysticercosis in Wisconsin: 3 cases and a review of the literature.
Topics: Adult; Albendazole; Anthelmintics; Diagnosis, Differential; Diagnostic Imaging; Drug Therapy, Combin | 2014 |
[Disseminated cysticercosis: report of three cases in Togo].
Topics: Albendazole; Animals; Anthelmintics; Anticonvulsants; Betamethasone; Cysticercosis; Epilepsy; Eye In | 2015 |
Neurocysticercosis: Diagnostic problems & current therapeutic strategies.
Topics: Albendazole; Animals; Brain; Epilepsy; Humans; India; Neurocysticercosis; Red Meat; Swine; Taenia so | 2016 |
Intramedullary spinal cysticercosis cured with medical therapy: case report and review of literature.
Topics: Adult; Albendazole; Anti-Inflammatory Agents; Anticestodal Agents; Back Pain; Dexamethasone; Drug Th | 2009 |
Anthelmintics for people with neurocysticercosis.
Topics: Adult; Albendazole; Anticestodal Agents; Brain Diseases; Child; Humans; Neurocysticercosis; Praziqua | 2010 |
Anthelmintics for people with neurocysticercosis.
Topics: Adrenal Cortex Hormones; Adult; Albendazole; Anticestodal Agents; Brain Diseases; Child; Humans; Neu | 2010 |
Medical management of neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Brain Diseases; Humans; Life Cycle Stages; Magnetic Resonance I | 2011 |
Pharmacokinetic variability of anthelmintics: implications for the treatment of neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Humans; Neurocysticercosis; Praziquantel; Treatment Outcome | 2012 |
Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis.
Topics: Adolescent; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Calcinosis; Child; Child, Preschoo | 2013 |
Corticosteroids for neurocysticercosis: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adrenal Cortex Hormones; Adult; Albendazole; Child; Drug Combinations; Humans; Magnetic Resonance Im | 2013 |
Neurocysticercosis--New Millennium, ancient disease and unending debate.
Topics: Albendazole; Animals; Anthelmintics; Anticonvulsants; Humans; Neurocysticercosis; Praziquantel; Seiz | 2003 |
[Brain cysticercosis: review and case report].
Topics: Adult; Albendazole; Animals; Anthelmintics; Brain Diseases; Brain Edema; Diagnostic Errors; Emigrati | 2003 |
Intramedullary cysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Humans; Magnetic Resonance Imaging; Male; Medulla Oblongata; Musc | 2004 |
Imaging of neurocysticercosis.
Topics: Albendazole; Anticestodal Agents; Diagnosis, Differential; Humans; Magnetic Resonance Imaging; Neuro | 2004 |
[A case of cerebral coenurosis].
Topics: Albendazole; Animals; Anthelmintics; Anti-Inflammatory Agents; Ataxia; Brain Stem; Central Nervous S | 2004 |
Therapy for neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Clinical Trials as Topic; Humans; Neurocysticercosis; Practice | 2004 |
Intraventricular neurocysticercosis: 18 consecutive patients and review of the literature.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Cerebral Ventricles; Diagnosis, Differential; F | 2002 |
[Neurocysticercosis: up-dating in diagnosis and treatment].
Topics: Albendazole; Animals; Anthelmintics; Antibodies; Humans; Neurocysticercosis; Praziquantel; Taenia so | 2005 |
Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel.
Topics: Albendazole; Anthelmintics; Humans; Neurocysticercosis; Praziquantel; Radiography; Secondary Prevent | 2006 |
[Treatment of neurocysticercosis: a review].
Topics: Albendazole; Animals; Anthelmintics; Bacterial Vaccines; Evidence-Based Medicine; Humans; Neurocysti | 2006 |
Treatment of intramedullary spinal cysticercosis: report of 2 cases and review of literature.
Topics: Adult; Albendazole; Anthelmintics; Cervical Vertebrae; Child; Female; Humans; Laminectomy; Neurocyst | 2007 |
Does albendazole affect seizure remission and computed tomography response in children with neurocysticercosis? A Systematic review and meta-analysis.
Topics: Albendazole; Antiparasitic Agents; Child; Child, Preschool; Databases, Factual; Humans; Neurocystice | 2007 |
WITHDRAWN: Drugs for treating neurocysticercosis (tapeworm infection of the brain).
Topics: Albendazole; Anticestodal Agents; Brain Diseases; Humans; Neurocysticercosis; Praziquantel; Trichlor | 2007 |
Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.
Topics: Albendazole; Clinical Trials as Topic; Humans; Neurocysticercosis; Praziquantel; Randomized Controll | 2008 |
[Neurocysticercosis].
Topics: Albendazole; Animals; Anticestodal Agents; Diagnosis, Differential; Host-Parasite Interactions; Huma | 1999 |
Treating neurocysticercosis medically: a systematic review of randomized, controlled trials.
Topics: Albendazole; Anthelmintics; Anticestodal Agents; Humans; Neurocysticercosis; Praziquantel; Randomize | 1999 |
Drugs for treating neurocysticercosis (tapeworm infection of the brain).
Topics: Albendazole; Anticestodal Agents; Brain Diseases; Humans; Neurocysticercosis; Praziquantel; Trichlor | 2000 |
[A case report of mixed, parenchymatous and meningo-basal neurocysticercosis].
Topics: Adult; Albendazole; Anticestodal Agents; Brain; Dexamethasone; Drug Therapy, Combination; Electroenc | 2000 |
36 trials available for albendazole and Central Nervous System Cysticercosis
| Article | Year |
|---|---|
Efficacy of Combination Therapy of Albendazole and Praziquantel vs Albendazole Monotherapy in Children With Persistent Neurocysticercosis: A Randomized Controlled Trial.
Topics: Adolescent; Albendazole; Anthelmintics; Child; Child, Preschool; Drug Therapy, Combination; Humans; | 2022 |
Fourteen Days vs 28 Days of Albendazole Therapy for Neurocysticercosis in Children: An Open Label Randomized Controlled Trial.
Topics: Albendazole; Anthelmintics; Calcinosis; Child; Drug Therapy, Combination; Humans; Neurocysticercosis | 2022 |
A longitudinal analysis of albendazole treatment effect on neurocysticercosis cyst evolution using multistate models.
Topics: Adult; Albendazole; Animals; Anticestodal Agents; Disease Progression; Female; Humans; Longitudinal | 2019 |
T2 relaxometry helps prognosticate seizure outcome in patients with solitary cerebral cysticercosis.
Topics: Adolescent; Adult; Albendazole; Anticonvulsants; Brain; Child; Child, Preschool; Chronic Disease; Dr | 2017 |
The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis.
Topics: Administration, Oral; Albendazole; Animals; Anthelmintics; Double-Blind Method; Drug Administration | 2018 |
Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Anthelmintics; Child; Child, Preschool; Dis | 2019 |
Quantitative serial T2 relaxometry: a prospective evaluation in solitary cerebral cysticercosis.
Topics: Albendazole; Algorithms; Anthelmintics; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female | 2014 |
Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Double-Blind Method; Drug-Related Side Effects | 2014 |
Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Double-Blind Method; Drug-Related Side Effects | 2014 |
Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Double-Blind Method; Drug-Related Side Effects | 2014 |
Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Double-Blind Method; Drug-Related Side Effects | 2014 |
The effect of albendazole treatment on seizure outcomes in patients with symptomatic neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Anti-Inflammatory Agents; Brain; Cysts; Drug Therapy, Combinati | 2015 |
Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis.
Topics: Adolescent; Adult; Albendazole; Animals; Anticestodal Agents; Brain Diseases; Female; Humans; Male; | 2016 |
Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial.
Topics: Adolescent; Albendazole; Animals; Anthelmintics; Child; Child, Preschool; Double-Blind Method; Drug | 2009 |
Natural history of solitary cerebral cysticercosis on serial magnetic resonance imaging and the effect of albendazole therapy on its evolution.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Brain; Child; Cohort Studies; Contrast Media; Disease | 2010 |
Natural history of solitary cerebral cysticercosis cases after albendazole therapy: a longitudinal follow-up study from India.
Topics: Albendazole; Humans; India; Longitudinal Studies; Neurocysticercosis; Time Factors; Treatment Outcom | 2010 |
Three day albendazole therapy in patients with a solitary cysticercus granuloma: a randomized double blind placebo controlled study.
Topics: Adolescent; Adult; Albendazole; Anticestodal Agents; Anticonvulsants; Child; Child, Preschool; Doubl | 2010 |
Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Drug Therapy, Combination; Female; Humans; M | 2011 |
Perilesional gliosis around solitary cerebral parenchymal cysticerci and long-term seizure outcome: a prospective study using serial magnetization transfer imaging.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Anticonvulsants; Brain; Child; Child, Preschool; Drug | 2011 |
Three-day versus 15-day course of albendazole therapy in solitary cysticercus granuloma: an open label randomized trial.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Child; Child, Preschool; Cysticercus; Drug A | 2012 |
One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial.
Topics: Administration, Oral; Albendazole; Anthelmintics; Chi-Square Distribution; Child; Child, Preschool; | 2003 |
Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial.
Topics: Adolescent; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Anticonvulsants; Brain; Brain Edem | 2003 |
A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis.
Topics: Adolescent; Adult; Aged; Albendazole; Anti-Inflammatory Agents; Anticestodal Agents; Anticonvulsants | 2004 |
Pre-treatment with corticosteroids and a single cycle of high dose albendazole for subarachnoidal cysticercosis.
Topics: Adrenal Cortex Hormones; Adult; Albendazole; Anthelmintics; Antigens, Helminth; Arachnoid; Cerebrosp | 2004 |
Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis.
Topics: Adolescent; Albendazole; Anticestodal Agents; Brain; Brain Diseases; Child; Child, Preschool; Drug T | 2004 |
Parkinsonism associated with neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Antiparkinson Agents; Brain; Female; Humans; Levodopa; Magnetic R | 2005 |
Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis.
Topics: Adult; Albendazole; Anticestodal Agents; Cerebral Ventricles; Dexamethasone; Dose-Response Relations | 2006 |
Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Carbamazepine; Cerebral Cortex; Child; Child, Prescho | 2008 |
Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study.
Topics: Adult; Albendazole; Anthelmintics; Antiparasitic Agents; Brain; Electroencephalography; Enzyme-Linke | 2007 |
Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Albendazole; Anti-Inflammatory Agents; Antiparasitic Agents; Brain; | 2008 |
Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial.
Topics: Adolescent; Albendazole; Animals; Anthelmintics; Brain; Child; Child, Preschool; Double-Blind Method | 1998 |
Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Area Under Curve; Chromatography, High Pressure | 1999 |
Single-day praziquantel versus 1-week albendazole for neurocysticercosis.
Topics: Adult; Aged; Albendazole; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neurocyst | 1999 |
Clinical pharmacokinetics of albendazole in children with neurocysticercosis.
Topics: Adolescent; Albendazole; Anthelmintics; Area Under Curve; Child; Child, Preschool; Chromatography, H | 1997 |
Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy.
Topics: Albendazole; Anthelmintics; Brain Diseases; Child; Child, Preschool; Diagnosis, Differential; Female | 2000 |
Cysticidal therapy: impact on seizure control in epilepsy associated with neurocysticercosis.
Topics: Adult; Aged; Albendazole; Anticestodal Agents; Epilepsy; Follow-Up Studies; Humans; Magnetic Resonan | 2000 |
Albendazole therapy for solitary persistent cysticercus granuloma.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Child; Female; Granuloma; Humans; Male; Middle Aged; | 2001 |
Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Anticestodal Agents; Brain Diseases; Dexame | 2001 |
Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Anticonvulsants; Area Under Curve; Carbamazepine; Chromatography, | 2002 |
204 other studies available for albendazole and Central Nervous System Cysticercosis
| Article | Year |
|---|---|
Comparison of Long-Term Outcomes Between 7 Days and 28 Days Albendazole Monotherapy in the Treatment of Single-Lesion Neurocysticercosis in Children.
Topics: Adolescent; Albendazole; Anthelmintics; Child; Female; Follow-Up Studies; Humans; Male; Neurocystice | 2022 |
Oxfendazole induces protein catabolism and gluconeogenesis in experimental neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Benzimidazoles; Cysticercus; Gluconeogenesis; Mice; Mice, Inbre | 2022 |
Neurocysticercosis Complicating Pregnancy.
Topics: Albendazole; Anthelmintics; Female; Headache; Humans; Hydrocephalus; Infant, Newborn; Neurocysticerc | 2022 |
Cerebral Taenia crassiceps larvae infection in a 71-year-old immunocompetent male.
Topics: Aged; Albendazole; Animals; Humans; Larva; Male; Neurocysticercosis; Taenia | 2023 |
Efficacy and safety of praziquantel in the treatment of neurocysticercosis in Vietnam.
Topics: Alanine Transaminase; Albendazole; Anthelmintics; Anticonvulsants; Antiparasitic Agents; Aspartate A | 2022 |
Value of whole-body MRI for the assessment of response to albendazole in disseminated neurocysticercosis: a prospective follow-up study.
Topics: Albendazole; Anthelmintics; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Neurocysticercosi | 2023 |
[A Histopathologically Diagnosed Neurocysticercosis Case from Türkiye].
Topics: Albendazole; Animals; Brain; Cysticercosis; Cysts; Humans; Neurocysticercosis; Swine | 2022 |
[A Histopathologically Diagnosed Neurocysticercosis Case from Türkiye].
Topics: Albendazole; Animals; Brain; Cysticercosis; Cysts; Humans; Neurocysticercosis; Swine | 2022 |
[A Histopathologically Diagnosed Neurocysticercosis Case from Türkiye].
Topics: Albendazole; Animals; Brain; Cysticercosis; Cysts; Humans; Neurocysticercosis; Swine | 2022 |
[A Histopathologically Diagnosed Neurocysticercosis Case from Türkiye].
Topics: Albendazole; Animals; Brain; Cysticercosis; Cysts; Humans; Neurocysticercosis; Swine | 2022 |
Albendazole for Neurocysticercosis in Children: How Long is Long Enough?
Topics: Albendazole; Anthelmintics; Child; Humans; Neurocysticercosis | 2022 |
Albendazole for Neurocysticercosis in Children: How Long is Long Enough?
Topics: Albendazole; Anthelmintics; Child; Humans; Neurocysticercosis | 2022 |
Albendazole for Neurocysticercosis in Children: How Long is Long Enough?
Topics: Albendazole; Anthelmintics; Child; Humans; Neurocysticercosis | 2022 |
Albendazole for Neurocysticercosis in Children: How Long is Long Enough?
Topics: Albendazole; Anthelmintics; Child; Humans; Neurocysticercosis | 2022 |
Efficacy and safety of antiparasitic therapy for neurocysticercosis in rural Tanzania: a prospective cohort study.
Topics: Albendazole; Anthelmintics; Antiparasitic Agents; Cysts; Humans; Neurocysticercosis; Praziquantel; P | 2023 |
Prolonged Albendazole Therapy for Neurocysticercosis in Children.
Topics: Albendazole; Anthelmintics; Child; Humans; Neurocysticercosis; Seizures | 2023 |
Prolonged Albendazole Therapy for Neurocysticercosis in Children: Author's Reply.
Topics: Albendazole; Anthelmintics; Child; Humans; Neurocysticercosis; Seizures | 2023 |
Albendazole - Ivermectin combination decreases inflammation in experimental neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Anti-Inflammatory Agents; Cysticercus; Inflammation; Ivermectin | 2023 |
Colloidal/Calcified
Topics: Adult; Albendazole; Hospitals; Humans; Neurocysticercosis; Saudi Arabia; Seizures | 2023 |
Disseminated neurocysticercosis with bilateral papilledema: a case report.
Topics: Albendazole; Antiprotozoal Agents; Cysticercosis; Dexamethasone; Glucocorticoids; Humans; Male; Neur | 2019 |
Do albendazole-loaded lipid nanocapsules enhance the bioavailability of albendazole in the brain of healthy mice?
Topics: Albendazole; Animals; Anthelmintics; Biological Availability; Brain; Disease Models, Animal; Humans; | 2020 |
Natural History of Treated Subarachnoid Neurocysticercosis.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Anti-Inflammatory Agents; Antigens, Helminth | 2020 |
Cysticidal activity of praziquantel-mebendazole combination: In vitro and in vivo studies.
Topics: Albendazole; Animals; Anthelmintics; Blood-Brain Barrier; Cysticercosis; Drug Combinations; Mebendaz | 2020 |
In vitro nitazoxanide exposure affects energetic metabolism of Taenia crassiceps.
Topics: Albendazole; Analysis of Variance; Animals; Anthelmintics; Antiparasitic Agents; Citrates; Citric Ac | 2020 |
Long-lasting undetected neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Brain; Histocytochemistry; Humans; Immunoassay; Magnetic Resona | 2019 |
Quantitative assessment of lesion load and efficacy of 3 cycles of albendazole in disseminated cysticercosis: a prospective evaluation.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Albendazole; Animals; Anthelmintics; Anticonvulsants; Br | 2020 |
Histopathologic evaluation of experimental murine neurocysticercosis after treatment with albendazole/nitazoxanide combination.
Topics: Albendazole; Animals; Anticestodal Agents; Disease Models, Animal; Drug Combinations; Female; Mice; | 2020 |
Lumbosacral Radiculopathy as the Clinical Presentation of Neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Antibodies, Helminth; Female; Humans; I | 2020 |
Frequency and Determinant Factors for Calcification in Neurocysticercosis.
Topics: Albendazole; Animals; Antiparasitic Agents; Brain; Humans; Neurocysticercosis; Seizures; Taenia soli | 2021 |
Radiographic Improvement of Larval Cysts in Neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Anticonvulsants; Brain; Humans; Magnetic Resonance Imaging; Male; | 2021 |
[Disseminated cysticercosis affecting the brain, the eye and the skin on a Senegalese patient].
Topics: Aged; Albendazole; Brain; Cysticercosis; Diagnosis, Differential; Eye; Eye Infections, Parasitic; Fe | 2020 |
A case of neurocysticercosis with an unusual presentation on high seas.
Topics: Albendazole; Animals; Anticestodal Agents; Brain; Humans; India; Magnetic Resonance Imaging; Male; N | 2020 |
Management of Neurocysticercosis in Children: Association of Child Neurology Consensus Guidelines.
Topics: Albendazole; Child; Humans; Neurocysticercosis; Neurology; Phenytoin; Seizures | 2021 |
Intramedullary Neurocysticercosis Successfully Treated with Medical Therapy.
Topics: Albendazole; Anthelmintics; Anti-Inflammatory Agents; Child; Dexamethasone; Drug Therapy, Combinatio | 2017 |
Spinal racemose cysticercosis: case report and review.
Topics: Adrenal Cortex Hormones; Albendazole; Brain; Decompressive Craniectomy; Humans; Magnetic Resonance I | 2017 |
Time trend of neurocysticercosis in children with seizures in a tertiary hospital of western Nepal.
Topics: Adolescent; Albendazole; Anthelmintics; Child; Child, Preschool; Female; Follow-Up Studies; Humans; | 2017 |
Radiological evolution of porcine neurocysticercosis after combined antiparasitic treatment with praziquantel and albendazole.
Topics: Albendazole; Animals; Anthelmintics; Brain; Cysts; Disease Models, Animal; Drug Therapy, Combination | 2017 |
Primary Intradural Extramedullary Cervical Spinal Cysticercosis.
Topics: Albendazole; Cervical Vertebrae; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurocystice | 2017 |
Adhesion molecules, chemokines and matrix metallo-proteinases response after albendazole and albendazole plus steroid therapy in swine neurocysticercosis.
Topics: Albendazole; Animals; Antiprotozoal Agents; Brain; Cell Adhesion Molecules; Chemokines; Drug Therapy | 2017 |
A fatal case of malignant neurocysticercosis.
Topics: Adult; Albendazole; Antiprotozoal Agents; Brain; Dexamethasone; Fatal Outcome; Female; Glucocorticoi | 2017 |
Giant Intraparanchymal Neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Anticonvulsants; Brain; Craniotomy; Dissection; Glucocorticoids; | 2017 |
Pregnancy Screening and Monitoring of Albendazole Therapy for Neurocysticercosis.
Topics: Albendazole; Anthelmintics; Humans; Hygiene; Neurocysticercosis; Pregnancy; Tropical Medicine; Unite | 2018 |
Antiparasitic Dosing Discrepancy in the 2017 Neurocysticercosis Guidelines.
Topics: Albendazole; Antiparasitic Agents; Humans; Hygiene; Neurocysticercosis; Tropical Medicine; United St | 2018 |
[Clinical Analysis of 94 Patients with Neurocysticercosis in Sichuan Province].
Topics: Adult; Albendazole; Antibodies; China; Diagnostic Errors; Enzyme-Linked Immunosorbent Assay; Female; | 2016 |
Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis.
Topics: Adult; Age Factors; Albendazole; Anthelmintics; Dexamethasone; Drug Therapy, Combination; Female; Hu | 2019 |
Etanercept to Control Inflammation in the Treatment of Complicated Neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Anti-Inflammatory Agents, Non-Steroidal; Etanercept; Female; Huma | 2019 |
Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Chromatography, High Pressure Liquid; Female; H | 2019 |
Health Care Without Borders: A Case Report of an Immigrant Child Who Lost His Voice.
Topics: Adolescent; Albendazole; Anthelmintics; Anticonvulsants; Brain; Brain Diseases; Emigrants and Immigr | 2019 |
Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology.
Topics: Academies and Institutes; Albendazole; Anticestodal Agents; Clinical Trials as Topic; Databases, Fac | 2013 |
[Cerebral cysticerc is a rare cause of hydrocephalus].
Topics: Adult; Albendazole; Anthelmintics; Fatal Outcome; Female; HIV Seropositivity; Humans; Hydrocephalus; | 2013 |
Massive non-encephalitic neurocysticercosis.
Topics: Albendazole; Anticestodal Agents; Brain; Encephalitis; Humans; Magnetic Resonance Imaging; Male; Mid | 2013 |
Evidence-based guideline: Treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology.
Topics: Academies and Institutes; Albendazole; Anticestodal Agents; Evidence-Based Medicine; Female; Humans; | 2013 |
Cerebral mass in HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Albendazole; Anthelmintics; Diagnosis, Differential; F | 2013 |
Concurrent asymptomatic inflammatory aneurysm and ischemic stroke due to cysticercal arteritis.
Topics: Adult; Albendazole; Aneurysm, Infected; Angiography, Digital Subtraction; Anthelmintics; Anti-Inflam | 2013 |
Evidence-based guideline: Treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology.
Topics: Academies and Institutes; Albendazole; Anticestodal Agents; Evidence-Based Medicine; Female; Humans; | 2013 |
Evidence-based guideline: Treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology.
Topics: Academies and Institutes; Albendazole; Anticestodal Agents; Evidence-Based Medicine; Female; Humans; | 2013 |
Author response.
Topics: Academies and Institutes; Albendazole; Anticestodal Agents; Evidence-Based Medicine; Female; Humans; | 2013 |
Acute hydrocephalus caused by intraspinal neurocysticercosis: case report.
Topics: Albendazole; Brain Damage, Chronic; Combined Modality Therapy; Decompression, Surgical; Dexamethason | 2014 |
Partial reverse of the TCA cycle is enhanced in Taenia crassiceps experimental neurocysticercosis after in vivo treatment with anthelminthic drugs.
Topics: Albendazole; Animals; Anthelmintics; Brain; Chromatography, High Pressure Liquid; Citric Acid Cycle; | 2014 |
[Neurocysticercosis: five years follow-up of 21 patients].
Topics: Adrenal Cortex Hormones; Albendazole; Antiparasitic Agents; Female; Follow-Up Studies; Humans; Male; | 2013 |
Amaurosis fugax caused by neurocysticercosis.
Topics: Albendazole; Amaurosis Fugax; Anticestodal Agents; Brain; Child; Humans; Magnetic Resonance Imaging; | 2014 |
Parenchymal neurocysticercosis.
Topics: Adult; Albendazole; Animals; Humans; Male; Mexican Americans; Neurocysticercosis; Prednisone; Taenia | 2015 |
Seizure and radiological outcomes in children with solitary cysticercous granulomas with and without albendazole therapy: a retrospective case record analysis.
Topics: Albendazole; Anthelmintics; Anticonvulsants; Child; Child, Preschool; Female; Follow-Up Studies; Gra | 2014 |
Determining better treatments for neurocysticercosis.
Topics: Albendazole; Anthelmintics; Female; Humans; Male; Neurocysticercosis; Praziquantel | 2014 |
Treatment of neurocysticercosis.
Topics: Albendazole; Anthelmintics; Female; Humans; Male; Neurocysticercosis; Praziquantel | 2014 |
Millairy neurocysticercosis.
Topics: Albendazole; Anthelmintics; Brain Diseases; Child, Preschool; Drug Therapy, Combination; Humans; Mag | 2014 |
[Comparative study on EEG and neuroimaging of patients with cerebral cysticercosis before and after treatment].
Topics: Adolescent; Adult; Aged; Albendazole; Antiparasitic Agents; Electroencephalography; Female; Humans; | 2014 |
Difficult to control epilepsy in young female: a common problem in a low resource setting.
Topics: Adolescent; Albendazole; Anthelmintics; Anticonvulsants; Brain; Calcinosis; Drug Resistance; Epileps | 2014 |
Resolution of urticarial vasculitis after treatment of neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Humans; Male; Neurocysticercosis; Remission Induction; Urticaria; | 2015 |
[Temporal lobe epilepsy and active neurocysticercosis: two representative case reports].
Topics: Albendazole; Anomia; Anthelmintics; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Citalopram | 2015 |
Spinal cysticercosis: an unusual presentation.
Topics: Adult; Albendazole; Animals; Anticestodal Agents; Back Pain; Brown-Sequard Syndrome; Drug Therapy, C | 2015 |
Combined antiparasitic treatment for neurocysticercosis.
Topics: Albendazole; Anthelmintics; Female; Humans; Male; Neurocysticercosis; Praziquantel | 2015 |
Combined antiparasitic treatment for neurocysticercosis.
Topics: Albendazole; Anthelmintics; Female; Humans; Male; Neurocysticercosis; Praziquantel | 2015 |
Combined antiparasitic treatment for neurocysticercosis.
Topics: Albendazole; Anthelmintics; Female; Humans; Male; Neurocysticercosis; Praziquantel | 2015 |
Combined antiparasitic treatment for neurocysticercosis - Authors' reply.
Topics: Albendazole; Anthelmintics; Female; Humans; Male; Neurocysticercosis; Praziquantel | 2015 |
[Neurocysticercosis revealed by refractory epilepsy: report of a case].
Topics: Adult; Albendazole; Epilepsy; Humans; Male; Neurocysticercosis; Prednisolone | 2015 |
Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: Role of docosahexaenoic acid.
Topics: Administration, Intranasal; Albendazole; Animals; Anthelmintics; Anti-Inflammatory Agents, Non-Stero | 2015 |
[Neurocysticercosis].
Topics: Albendazole; Animals; Anthelmintics; Drug Therapy, Combination; Humans; Magnetic Resonance Imaging; | 2015 |
Successful Antiparasitic Treatment for Cysticercosis is Associated with a Fast and Marked Reduction of Circulating Antigen Levels in a Naturally Infected Pig Model.
Topics: Albendazole; Animals; Anticestodal Agents; Antigens, Helminth; Benzimidazoles; Cysticercosis; Diseas | 2015 |
Neurocysticercosis with Diplopia Responds Well to Albendazole.
Topics: Adrenal Cortex Hormones; Albendazole; Animals; Anticestodal Agents; Brain; Diplopia; Female; Humans; | 2016 |
Neurocysticercosis presenting as a 'Stroke Mimic'.
Topics: Albendazole; Anticestodal Agents; Brain; Diagnosis, Differential; Glucocorticoids; Humans; Magnetic | 2016 |
Long-term Clinical and Radiologic Outcome in 500 Children With Parenchymal Neurocysticercosis.
Topics: Adolescent; Albendazole; Anticestodal Agents; Child; Child, Preschool; Female; Follow-Up Studies; Hu | 2017 |
Clinical analysis of 52 cases of neurocysticercosis.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Brain; Brain Diseases; Child; China; Female; Humans; | 2008 |
Treatment of neurocysticercosis: a randomised controlled trial.
Topics: Albendazole; Antiparasitic Agents; Brain; Humans; Neurocysticercosis; Taeniasis | 2008 |
[Degenerating neurocysticercosis cysts: differential diagnosis with cerebral metastasis].
Topics: Adrenal Cortex Hormones; Aged; Albendazole; Anthelmintics; Biopsy; Brain Diseases; Brain Neoplasms; | 2008 |
Isolated spinal neurocysticercosis with clinical pleomorphism.
Topics: Adult; Albendazole; Anthelmintics; Cervical Vertebrae; Humans; Magnetic Resonance Imaging; Male; Neu | 2008 |
First case report of pharyngeal cysticercosis.
Topics: Aged, 80 and over; Albendazole; Animals; Anthelmintics; Cysticercosis; Diagnosis, Differential; Fema | 2009 |
Neurocysticercosis in a patient in Canada.
Topics: Albendazole; Anti-Inflammatory Agents; Anticonvulsants; Antiprotozoal Agents; Brain; Brain Diseases; | 2009 |
Intraventricular neurocysticercosis managed with albendazole and dexamethasone.
Topics: Adult; Albendazole; Anti-Inflammatory Agents; Antiprotozoal Agents; Dexamethasone; Female; Humans; I | 2009 |
Isolated third cranial nerve palsy: a rare presentation of neurocysticercosis.
Topics: Adolescent; Albendazole; Anti-Inflammatory Agents; Anticestodal Agents; Dexamethasone; Humans; Male; | 2011 |
[Wallenberg syndrome and neurocysticercosis: about one case in Ouagadougou, Burkina Faso].
Topics: Adult; Albendazole; Antiprotozoal Agents; Brain; Glucocorticoids; Humans; Lateral Medullary Syndrome | 2009 |
Headache as the initial manifestation of neurocysticercosis: a case of eosinophilic meningitis.
Topics: Adult; Albendazole; Antibodies; Brain; Calcinosis; Dexamethasone; Eosinophilia; Headache; Humans; Im | 2009 |
Intraventricular and subarachnoid basal cisterns neurocysticercosis: a comparative study between traditional treatment versus neuroendoscopic surgery.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Cerebral Ventricles; Child; Female; Follow-Up S | 2009 |
A 44-year-old man with neurocysticercosis.
Topics: Adult; Albendazole; Animals; Anthelmintics; Anticonvulsants; Brain; Emergency Service, Hospital; Epi | 2009 |
Neurocysticercosis in the infant of a pregnant mother with a tapeworm.
Topics: Albendazole; Animals; Anthelmintics; Anti-Inflammatory Agents; Anticonvulsants; Carbamazepine; Dexam | 2009 |
Population pharmacokinetics of albendazole in patients with neurocysticercosis.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Biological Availability; Chromatography, High P | 2009 |
[About an autochtonous case of neurocysticercosis in Mali].
Topics: Albendazole; Anthelmintics; Brain Edema; Calcinosis; Consciousness Disorders; Diet; Drug Therapy, Co | 2009 |
Multiple lobulated cystic lesions in suprasellar cistern.
Topics: Adult; Albendazole; Antiparasitic Agents; Frontal Lobe; Humans; Hydrocephalus; Male; Neurocysticerco | 2009 |
Subarachnoidal Neurocysticercosis non-responsive to cysticidal drugs: a case series.
Topics: Adult; Aged; Albendazole; Anthelmintics; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Me | 2010 |
Acute hydrocephalus secondary to neurocysticercosis.
Topics: Acute Disease; Adult; Albendazole; Animals; Anticestodal Agents; Cerebral Aqueduct; Headache; Humans | 2012 |
Epileptiform seizures revealing neurocysticercosis: report of two clinical cases in Libreville, Gabon.
Topics: Adrenal Cortex Hormones; Adult; Albendazole; Animals; Antibodies, Helminth; Anticestodal Agents; Fem | 2010 |
Claude's syndrome associated with neurocysticercosis.
Topics: Aged; Albendazole; Brain; Brain Stem Infarctions; Edema; Humans; Magnetic Resonance Imaging; Male; N | 2010 |
Intraventricular neurocysticercosis causing acute unilateral hydrocephalus.
Topics: Acute Disease; Adult; Albendazole; Anthelmintics; Female; Humans; Hydrocephalus; Lateral Ventricles; | 2010 |
[Neurocysticercosis in Murcia (Spain)].
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Bolivia; Child; Ecuador; Female; Humans; Incide | 2011 |
Monocular blindness during therapy for cerebral neurocysticercosis.
Topics: Adult; Albendazole; Anticestodal Agents; Anticonvulsants; Blindness; Brain Diseases; Dexamethasone; | 2010 |
Neurocysticercosis-induced hemiballismus in a child.
Topics: Albendazole; Animals; Anthelmintics; Child; Dyskinesias; Female; Glucocorticoids; Humans; Magnetic R | 2011 |
A simple LC-MS/MS method to determine plasma and cerebrospinal fluid levels of albendazole metabolites (albendazole sulfoxide and albendazole sulfone) in patients with neurocysticercosis.
Topics: Albendazole; Anthelmintics; Chromatography, Liquid; Drug Stability; Humans; Linear Models; Neurocyst | 2012 |
Extraparenchymal neurocysticercosis.
Topics: Adult; Albendazole; Cerebral Ventricles; Combined Modality Therapy; Dexamethasone; Drainage; Follow- | 2011 |
Neurocysticercosis in Qatari patients: case reports.
Topics: Adolescent; Albendazole; Animals; Anti-Inflammatory Agents; Anticestodal Agents; Anticonvulsants; Br | 2011 |
Short report: A calcified Taenia solium granuloma associated with recurrent perilesional edema causing refractory seizures: histopathological features.
Topics: Albendazole; Animals; Anthelmintics; Anticonvulsants; Calcinosis; Edema; Granuloma; Humans; Levetira | 2011 |
Stars in the sky: neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Anticonvulsants; Diagnosis, Differential; Diuretics, Osmotic; Dru | 2012 |
Cysticercosis of the spinal cord.
Topics: Adolescent; Albendazole; Anthelmintics; Dexamethasone; Drug Therapy, Combination; Humans; Magnetic R | 2013 |
Incidental consequences of antihelmintic treatment in the central nervous system.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Central Nervous System; Central Nervous System Protoz | 2013 |
Disseminated cysticercosis in a child.
Topics: Albendazole; Antiprotozoal Agents; Child; Humans; Magnetic Resonance Imaging; Male; Neurocysticercos | 2012 |
An acquired source of seizures.
Topics: Adult; Albendazole; Animals; Anti-Inflammatory Agents; Anticonvulsants; Antiparasitic Agents; Develo | 2012 |
Primary extensive spinal subarachnoid cysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Cervical Vertebrae; Combined Modality Therapy; Humans; Laminect | 2012 |
Neurocysticercosis case with tuberculoma-like epithelioid granuloma strongly suspected by serology and confirmed by mitochondrial DNA.
Topics: Albendazole; Animals; Anthelmintics; Biopsy; Contrast Media; Diagnosis, Differential; DNA, Mitochond | 2011 |
Cysticercal encephalitis with cortical blindness.
Topics: Albendazole; Anti-Inflammatory Agents; Blindness, Cortical; Brain; Brain Edema; Calcinosis; Child; D | 2010 |
Bilateral ptosis: an atypical presentation of neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Blepharoptosis; Diagnosis, Differential; Female; Humans; Magnet | 2012 |
Neurocysticercosis in a 2-year-old boy infected at home.
Topics: Albendazole; Animals; Anthelmintics; Child, Preschool; Disease Transmission, Infectious; Family Heal | 2012 |
Neurocysticercosis presenting as a vertical one-and-a-half syndrome with associated contralesional horizontal gaze paresis.
Topics: Abducens Nerve Diseases; Adult; Albendazole; Anthelmintics; Blepharoptosis; Dexamethasone; Diagnosis | 2012 |
A persistent red eye and diplopia--when to neuroimage?
Topics: Adult; Albendazole; Anthelmintics; Anticonvulsants; Dexamethasone; Diplopia; Female; Glucocorticoids | 2012 |
Herculean appearance due to disseminated cysticercosis: case report.
Topics: Albendazole; Anticestodal Agents; Brain; Cysticercosis; Humans; Hypertrophy; Magnetic Resonance Imag | 2012 |
In vitro analysis of albendazole sulfoxide enantiomers shows that (+)-(R)-albendazole sulfoxide is the active enantiomer against Taenia solium.
Topics: Albendazole; Alkaline Phosphatase; Animals; Anticestodal Agents; Neurocysticercosis; Praziquantel; S | 2013 |
Multiple brain parenchymal neurocysticercosis with extraocular muscle cysticercosis affecting levator palpebral superioris and superior rectus complex: an unusual association.
Topics: Albendazole; Anti-Inflammatory Agents; Anticestodal Agents; Blepharoptosis; Brain Diseases; Child; C | 2013 |
Seroconversion of neurocysticercosis occurring after anti-helminthic treatment.
Topics: Adult; Albendazole; Animals; Antibody Formation; Anticestodal Agents; Antigens, Helminth; Blotting, | 2012 |
Migraine-like visual hallucinations in occipital lesions of cysticercosis.
Topics: Adolescent; Adult; Albendazole; Anticonvulsants; Antiprotozoal Agents; Carbamazepine; Drug Therapy, | 2002 |
CSF-VP shunt placement and albendazole therapy for cerebral cysticercosis.
Topics: Albendazole; Anthelmintics; Child; Female; Humans; Neurocysticercosis; Ventriculoperitoneal Shunt | 2002 |
Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Female; Humans; Male; Middle Aged; Neurocysticerc | 2002 |
Neurocysticercosis and the global world.
Topics: Adult; Albendazole; Anthelmintics; Brain; Female; Humans; Neurocysticercosis | 2002 |
[Diagnosis of neurocysticercosis: a case report].
Topics: Aged; Albendazole; Anthelmintics; Dysarthria; Endemic Diseases; Enzyme-Linked Immunosorbent Assay; E | 2001 |
Neurocysticercosis in children: clinical characteristics and outcome.
Topics: Adolescent; Age Distribution; Albendazole; Anticestodal Agents; Anticonvulsants; Child; Child, Presc | 2002 |
[Changes in computed tomogram in cerebral parenchymal cysticercosis treated with albendazole].
Topics: Adolescent; Adult; Aged; Albendazole; Anticestodal Agents; Child; Child, Preschool; Female; Humans; | 1999 |
Follow-up of neurocysticercosis patients after treatment using an antigen detection ELISA.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Antigens, Helminth; Brain; Cameroon; Child; Dev | 2003 |
Prolonged perilesional edema after treatment of parenchymal neurocysticercosis: methotrexate as a corticosteroid-sparing agent.
Topics: Adrenal Cortex Hormones; Albendazole; Animals; Anthelmintics; Edema; Humans; Male; Methotrexate; Mid | 2003 |
Successful treatment of isolated cerebellar cysticercosis with albendazole.
Topics: Adult; Albendazole; Cerebellar Diseases; Humans; Magnetic Resonance Imaging; Male; Neurocysticercosi | 2003 |
[Therapeutic efficacy of praziquantel, albendazole and a combination of the two drugs in cysticercosis].
Topics: Adult; Albendazole; Anthelmintics; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Neu | 2003 |
Unusual form of neurocysticercosis associated with HIV infection.
Topics: AIDS-Related Opportunistic Infections; Albendazole; Animals; Anthelmintics; Brain; Cysts; Epidural S | 2004 |
Tapeworms and seizures--treatment and prevention.
Topics: Albendazole; Animals; Anticestodal Agents; Brain Diseases; Developing Countries; Humans; Life Cycle | 2004 |
Neurocysticercosis--is the elimination of parasites beneficial?
Topics: Albendazole; Anticestodal Agents; Brain Diseases; Follow-Up Studies; Granuloma; Humans; Neurocystice | 2004 |
Corticosteroids, central serous chorioretinopathy, and neurocysticercosis.
Topics: Adult; Albendazole; Anticonvulsants; Antiprotozoal Agents; Body Fluids; Combined Modality Therapy; D | 2004 |
[Diagnostic image (174). A Nicaraguan man with an epileptic seizure. Neurocysticercosis].
Topics: Albendazole; Anthelmintics; Epilepsy; Food Contamination; Food Parasitology; Humans; Male; Middle Ag | 2004 |
Anticysticercal treatment and seizures in neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Clinical Trials as Topic; Humans; Neurocysticercosis; Praziquan | 2004 |
[Ecuadorian immigrant with headache].
Topics: Adrenal Cortex Hormones; Adult; Albendazole; Anthelmintics; Drug Therapy, Combination; Ecuador; Fema | 2004 |
A trial of antiparasitic treatment for cerebral cysticercosis.
Topics: Albendazole; Anti-Inflammatory Agents; Anticestodal Agents; Dexamethasone; Drug Therapy, Combination | 2004 |
A trial of antiparasitic treatment for cerebral cysticercosis.
Topics: Abdominal Pain; Albendazole; Animals; Anti-Inflammatory Agents; Anticestodal Agents; Dexamethasone; | 2004 |
Tapeworm headache.
Topics: Adult; Albendazole; Animals; Anthelmintics; Cerebral Ventricles; Headache; Humans; Magnetic Resonanc | 2004 |
Submandibular lymph node enlargement due to cysticercosis infestation.
Topics: Albendazole; Animals; Biopsy, Needle; Child; Drug Therapy, Combination; Female; Follow-Up Studies; H | 2004 |
Seizure outcome in patients with a solitary cerebral cysticercus granuloma.
Topics: Adolescent; Adult; Albendazole; Anticestodal Agents; Anticonvulsants; Child; Child, Preschool; Femal | 2004 |
Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis.
Topics: Adult; Albendazole; Female; Humans; Kidney; Kinetics; Male; Middle Aged; Molecular Structure; Neuroc | 2004 |
Transitory alexia without agraphia: a disconnection syndrome due to neurocysticercosis.
Topics: Aged; Albendazole; Alexia, Pure; Anthelmintics; Anti-Inflammatory Agents; Brain; Enzyme-Linked Immun | 2004 |
Syringohydromyelia associated to therapeutic procedures for severe forms of neurocysticercoses: case report.
Topics: Albendazole; Anthelmintics; Female; Humans; Neurocysticercosis; Severity of Illness Index; Syringomy | 2004 |
Neurocysticercosis: a rare cause of seizure.
Topics: Adult; Albendazole; Anticonvulsants; Drug Therapy, Combination; Epilepsy, Generalized; Follow-Up Stu | 2004 |
[Clinical study on the treatment of severe neurocysticercosis].
Topics: Adult; Albendazole; Anticestodal Agents; Female; Humans; Intracranial Hypertension; Male; Middle Age | 2004 |
Subdural cysticercosis mimicking a chronic subdural hematoma. Case illustration.
Topics: Aged; Aged, 80 and over; Albendazole; Brain Diseases; Diagnosis, Differential; Hematoma, Subdural, C | 2005 |
Bilateral disk edema with unilateral macular serous fluid secondary to neurocysticercosis.
Topics: Adult; Albendazole; Antiprotozoal Agents; Blood; Female; Functional Laterality; Humans; Macula Lutea | 2005 |
Disseminated cysticercosis involving orbit, brain and subcutaneous tissue.
Topics: Albendazole; Anti-Inflammatory Agents; Anticestodal Agents; Cysticercosis; Female; Humans; Magnetic | 2005 |
Neurocysticercosis.
Topics: Adult; Albendazole; Animals; Anthelmintics; Humans; Magnetic Resonance Imaging; Male; Neurocysticerc | 2005 |
A rare presentation of neurocysticercosis in a young child.
Topics: Albendazole; Anthelmintics; Humans; Infant; Male; Neurocysticercosis | 2005 |
Is dementia reversible in patients with neurocysticercosis?
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Dementia; Diagnostic and Statistical Manual of | 2005 |
Lateral sinus thrombosis in neurocysticercosis.
Topics: Adolescent; Albendazole; Anticestodal Agents; Humans; Male; Nepal; Neurocysticercosis; Sinus Thrombo | 2005 |
Late-onset eosinophilic chronic meningitis occurring 30 years after Taenia solium infestation in a white Caucasian woman.
Topics: Albendazole; Animals; Anthelmintics; Chronic Disease; Eosinophilia; Female; Glucocorticoids; Headach | 2006 |
[Clinical analysis of 32 cases with neurocysticercosis in children].
Topics: Adolescent; Albendazole; Anthelmintics; Child; Child, Preschool; Female; Humans; Male; Neurocysticer | 2005 |
Efficacy of a 3-day course of albendazole treatment in patients with a single neurocysticercosis cyst.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Brain Diseases; Drug Administration Schedule; Female; | 2006 |
Early recurrence of neurocysticercosis after orthotopic liver transplant.
Topics: Albendazole; Animals; Cerebral Cortex; Follow-Up Studies; Gadolinium; Graft Survival; Humans; Liver | 2006 |
Starry sky and beaded legs.
Topics: Adult; Albendazole; Anticestodal Agents; Anticonvulsants; Brain; Calcinosis; Female; Headache; Human | 2006 |
Neurocysticercosis an uncommon intra-cerebral infection in Malaysia.
Topics: Adult; Albendazole; Anthelmintics; Child; Female; Humans; Magnetic Resonance Imaging; Malaysia; Male | 2005 |
Short course of albendazole therapy for neurocysticercosis.
Topics: Albendazole; Anthelmintics; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-U | 2006 |
Multicystic tumor in the fourth ventricle: consider neurocysticercosis.
Topics: Albendazole; Anticestodal Agents; Central Nervous System Cysts; Cerebral Ventricles; Diagnosis, Diff | 2006 |
Superior divisional oculomotor nerve palsy caused by midbrain neurocysticercosis.
Topics: Adult; Albendazole; Anticestodal Agents; Female; Humans; Magnetic Resonance Imaging; Mesencephalon; | 2006 |
[Neurocysticercosis in a State of Piauí urban area: case report].
Topics: Adult; Albendazole; Animals; Anthelmintics; Brazil; Humans; Male; Neurocysticercosis; Tomography, X- | 2006 |
Picture of the month. Neurocysticercosis.
Topics: Adolescent; Albendazole; Animals; Antiprotozoal Agents; Humans; Life Cycle Stages; Magnetic Resonanc | 2006 |
Neurocysticercosis: surgical treatment of an autochthonous case in a non-endemic region.
Topics: Albendazole; Anthelmintics; Coma; Combined Modality Therapy; Craniotomy; Epilepsy, Generalized; Fron | 2006 |
Hemichorea resulting from single enhancing computed tomography lesion.
Topics: Albendazole; Anti-Dyskinesia Agents; Anticestodal Agents; Child; Chorea; Dyskinesias; Female; Follow | 2006 |
[Neurocysticercosis complicating the treatment of cutaneous cysticercosis in a traveller].
Topics: Adult; Albendazole; Anthelmintics; Brain Edema; Combined Modality Therapy; Confusion; Cysticercosis; | 2004 |
Neurocysticercosis uncovered by single-dose albendazole.
Topics: Adult; Albendazole; Animals; Antiparasitic Agents; Female; Humans; Neurocysticercosis; Seizures; Tae | 2007 |
Atypical ophthalmological presentation of neurocysticercosis in two children.
Topics: Albendazole; Anticestodal Agents; Child; Diagnosis, Differential; Drug Therapy, Combination; Eye Inf | 2007 |
[Neurocysticercosis].
Topics: Aged, 80 and over; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Humans; Magnetic Resonance | 2007 |
ELISA in the evaluation of therapeutic response to albendazole in neurocysticercosis.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Anthelmintics; Antibodies, Protozoan; Child; Child, P | 2008 |
Parotid gland cysticercosis.
Topics: Adult; Albendazole; Animals; Brain Edema; Humans; Male; Neurocysticercosis; Parotid Diseases; Paroti | 2007 |
Sudden-onset ptosis caused by midbrain neurocysticercosis in 2 children.
Topics: Acute Disease; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Blepharoptosis; Brain Diseases; | 2008 |
Albendazole therapy in patients with solitary cerebral cysticercus granuloma. Is it effective?
Topics: Albendazole; Anthelmintics; Brain Diseases; Granuloma; Humans; Neurocysticercosis; Research Design | 2008 |
Residual brain calcifications in neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Brain; Calcinosis; Female; Humans; Neurocysticercosis; Radiograph | 2008 |
Could neurocysticercosis be the cause of "onchocerciasis-associated" epileptic seizures?
Topics: Albendazole; Animals; Anthelmintics; Epilepsy; Humans; Neurocysticercosis; Onchocerca; Onchocerciasi | 2008 |
Treatment of cerebral cysticercosis with albendazole in elevated dosages.
Topics: Adult; Albendazole; Anticestodal Agents; Dexamethasone; Drug Therapy, Combination; Female; Glucocort | 2008 |
[Intracranial hypertension secondary to neurocysticercosis].
Topics: Albendazole; Antiparasitic Agents; Brain; Child; Female; Humans; Intracranial Hypertension; Magnetic | 2008 |
[Chronic brain edema in neurocysticercosis].
Topics: Adult; Albendazole; Anthelmintics; Brain Edema; Chlorpheniramine; Chronic Disease; Female; Histamine | 1998 |
Neurocysticercosis in an Italian traveler to Latin America.
Topics: Adult; Albendazole; Animals; Anthelmintics; Brain; Enzyme-Linked Immunosorbent Assay; Food Parasitol | 1999 |
Focal seizures with single small ring-enhancing lesion.
Topics: Acute Disease; Albendazole; Anthelmintics; Anticonvulsants; Brain Edema; Carbamazepine; Diagnosis, D | 1999 |
Relationship between cysticercosis and epilepsy.
Topics: Albendazole; Animals; Anthelmintics; Anticestodal Agents; Drug Administration Schedule; Epilepsy; Hu | 1999 |
Heavy nonencephalitic cerebral cysticercosis in tapeworm carriers. The Cysticercosis Working Group in Perú.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Albendazole; Animals; Anthelmintics; Brain Diseases; Car | 1999 |
Outcomes of medical treatment of neurocysticercosis: a study of 65 cases in Cheju Island, Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Anthelmintics; Female; Follow-Up Studies; H | 1999 |
Subcutaneous cysticercosis involving the eyelid: sonographic diagnosis.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Antiparasitic Agents; Cysticercosis; Eye Infections, | 2000 |
A case from India of neurocysticercosis responsive to albendazole treatment.
Topics: Adult; Albendazole; Animals; Anthelmintics; Brain; Central Nervous System Helminthiasis; Humans; Mag | 2000 |
Concomitant steroid and albendazole for treating neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Anti-Inflammatory Agents; Brain Edema; Child; Drug Therapy, Com | 1999 |
Clinical aspects of neurocysticercosis in children.
Topics: Albendazole; Anthelmintics; Antiprotozoal Agents; Brazil; Child; Child, Preschool; Eosinophils; Epil | 2000 |
Neurocysticercosis: migration and proliferation of cysticercus in a CSF valve.
Topics: Albendazole; Anthelmintics; Humans; Hydrocephalus; Male; Middle Aged; Neurocysticercosis; Praziquant | 2000 |
Neurocysticercosis in pregnancy: a case initially diagnosed as eclampsia.
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Cerebral Ventricles; Diagnosis, Differential; Ecl | 1999 |
Inflammatory aneurysm and neurocysticercosis: further evidence for a causal relationship? Case report.
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Cerebral Angiography; Humans; Inflammation; Intra | 2000 |
Praziquantel therapy in neurocysticercosis.
Topics: Albendazole; Anthelmintics; Brain; Humans; Neurocysticercosis; Praziquantel; Sensitivity and Specifi | 1996 |
[A case of neurocysticercosis presenting as focal seizure].
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Combined Modality Therapy; Humans; Male; Neurocys | 2000 |
The effects of albendazole solution at scolocidal concentration in the rat brain.
Topics: Albendazole; Animals; Anticestodal Agents; Brain; Dose-Response Relationship, Drug; Gliosis; Instill | 2000 |
Cysticercal dementia.
Topics: Aged; Albendazole; Dementia; Dexamethasone; Diagnosis, Differential; Humans; Intracranial Hypertensi | 1998 |
Neurocysticercosis: an unusual presentation of a rare disease.
Topics: Adult; Albendazole; Anthelmintics; Brain; Female; Humans; Neurocysticercosis | 2001 |
Late onset temporal lobe epilepsy with MRI evidence of mesial temporal sclerosis following acute neurocysticercosis: case report.
Topics: Acute Disease; Albendazole; Anthelmintics; Epilepsy, Temporal Lobe; Follow-Up Studies; Humans; Magne | 2001 |
Cerebral cysticercus granuloma associated with a subdural effusion.
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Epilepsy; Female; Granuloma; Humans; Magnetic Res | 2001 |
Ocular and orbital cysticercosis.
Topics: Adolescent; Adult; Albendazole; Antiprotozoal Agents; Child; Combined Modality Therapy; Cysticercosi | 2001 |
Bilateral cysticercosis of the optic nerve.
Topics: Adult; Albendazole; Antiprotozoal Agents; Cysts; Eye Infections, Parasitic; Humans; Magnetic Resonan | 2001 |
Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450.
Topics: Adult; Aged; Albendazole; Anthelmintics; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Biomar | 2002 |
Neurocysticercosis: an unusual presentation of a rare disease.
Topics: Albendazole; Anthelmintics; Calcinosis; Coma; Dexamethasone; Diagnosis, Differential; Humans; Intrac | 2002 |